

Thomas Jefferson University

**Reports on Federal Awards in
Accordance with OMB Uniform Guidance**

June 30, 2023

Federal Identification Number 23-1352651

Thomas Jefferson University
Reports on Federal Awards
in Accordance with OMB Uniform Guidance
Index
June 30, 2023

	Page(s)
I. CONSOLIDATED FINANCIAL STATEMENTS	
Report of Independent Auditors.....	i-iii
Consolidated Financial Statements and Notes to the Consolidated Financial Statements	3-50
Schedule of Expenditures of Federal Awards	51-69
Notes to Schedule of Expenditures of Federal Awards	70-72
II. REPORTS ON INTERNAL CONTROLS AND COMPLIANCE	
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	73-75
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with the Uniform Guidance.....	76-78
III. FINDINGS AND QUESTIONED COSTS	
Schedule of Findings and Questioned Costs	79-84
Summary Schedule of Prior Audit Findings	85-87
Management’s View and Corrective Action Plan.....	88-89
IV. SUPPLEMENTAL INFORMATION	
Schedule of Expenditures of Commonwealth of Pennsylvania Awards	90
Schedule of Expenditures of State of New Jersey Awards	91
Notes to the Supplemental Schedules.....	92
Schedule of Financial Responsibility Ratios	93-95



Report of Independent Auditors

To the Board of Trustees
Thomas Jefferson University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of Thomas Jefferson University and its subsidiaries (the “University”), which comprise the consolidated balance sheets as of June 30, 2023 and 2022, and the related consolidated statements of operations and changes in net assets without donor restrictions, of changes in net assets, and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of June 30, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University’s ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards*, will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if



there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2023 and schedules of financial responsibility ratios as of and for the year ended June 30, 2023 are presented for purposes of additional analysis as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the Department of Education, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and schedules of financial responsibility ratios are fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The supplementary information included in the Schedule of Expenditures of Federal Awards Supplementary Schedules, of the accompanying Consolidated Financial Statements for the year ended June 30, 2023, on pages 90-92 are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information has not been subjected to the auditing procedures applied in the audit of the consolidated financial statements and accordingly, we do not express an opinion or provide any assurance on them.



Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 20, 2023, except with respect to the opinion on the schedule of financial responsibility ratios, as to which the date is April 1, 2024, on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2023. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

Privatehouse Cooper LLP

Philadelphia, Pennsylvania

October 20, 2023, except with respect to the opinion on the schedule of financial responsibility ratios, as to which the date is April 1, 2024

I. Financial Statements

Thomas Jefferson University
Consolidated Balance Sheets
June 30, 2023 and 2022
(In Thousands)

	2023	2022
Assets		
Current assets:		
Cash and cash equivalents	\$743,046	\$403,988
Short-term investments	860,162	1,350,713
Accounts receivable	873,006	761,073
Insurance premium receivable	214,653	479,777
Inventory	151,767	152,398
Pledges receivable, current	41,266	25,654
Insurance recoverable, current	147,351	90,298
Assets whose use is limited, current	1,915	27,878
Other current assets	141,573	76,274
Total current assets	3,174,739	3,368,053
Long-term investments	2,954,704	2,725,639
Assets whose use is limited, noncurrent	209,986	375,694
Assets held by affiliated foundations	44,781	42,703
Pledges receivable, noncurrent	111,262	122,312
Goodwill	246,109	216,140
Insurance recoverable, noncurrent	316,575	302,319
Loans receivable from students, net	19,562	19,885
Land, buildings and equipment, net	4,188,135	3,954,950
Right-of-use assets	310,609	350,412
Other noncurrent assets	195,406	177,941
Total assets	\$11,771,868	\$11,656,048
Liabilities and Net Assets		
Current liabilities:		
Current portion of:		
Long-term obligations	\$47,818	\$92,281
Accrued professional liability claims	223,308	234,404
Accrued workers' compensation claims	17,633	21,570
Deferred revenues	29,739	30,381
Advances	19,536	196,822
Operating lease obligations	48,911	44,869
Accounts payable and accrued expenses	621,024	618,416
Medical costs payable	183,363	122,670
DHS insurance program payable	154,582	134,276
Accrued payroll and related costs	462,218	462,999
Total current liabilities	1,808,132	1,958,688
Long-term obligations	3,467,899	3,356,189
Accrued pension liability	243,893	401,111
Federal student loan advances	5,254	5,477
Accrued professional liability claims	663,336	616,458
Accrued workers' compensation claims	26,396	24,781
Interest rate hedges	11,987	18,211
Operating lease obligations	312,598	357,002
Other noncurrent liabilities	99,784	94,798
Total liabilities	6,639,279	6,832,715
Net assets:		
Net assets without donor restriction - Thomas Jefferson University	3,933,422	3,753,482
Noncontrolling interest in joint ventures	42,652	12,958
Total net assets without donor restriction	3,976,074	3,766,440
Net assets with donor restriction	1,156,515	1,056,893
Total net assets	5,132,589	4,823,333
Total liabilities and net assets	\$11,771,868	\$11,656,048

The accompanying notes are an integral part of the consolidated financial statements.

Thomas Jefferson University
Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions
For the Years Ended June 30, 2023 and 2022
(In Thousands)

	2023	2022
Operating revenues, gains and other support:		
Net patient service revenue	\$6,119,905	\$5,603,560
Insurance premium revenue	2,148,677	1,155,962
Grants and contracts	168,360	161,201
Tuition and fees, net	223,153	216,454
Investment income	163,899	88,573
Contributions	5,387	4,499
Other revenue	750,993	497,719
Government support for COVID-19	48,584	119,363
Net assets released from restrictions	71,529	67,154
Total operating revenues, gains and other support	<u>9,700,487</u>	<u>7,914,485</u>
Operating expenses:		
Salaries and wages	3,751,152	3,315,774
Employee benefits	884,529	726,609
Insurance services medical expenses	1,593,742	862,277
Supplies	1,357,436	1,222,440
Purchased services	855,947	750,065
Depreciation and amortization	358,567	328,303
Interest	116,406	83,995
Insurance	160,249	136,204
Utilities	70,509	73,982
Other	630,497	540,675
Total operating expenses	<u>9,779,034</u>	<u>8,040,324</u>
Loss from operations	<u>(78,547)</u>	<u>(125,839)</u>
Nonoperating items and other changes in net assets without donor restriction, net:		
Return on investments, net of amounts classified as operating revenue	106,827	(374,349)
Value of noncontrolling interest	28,386	-
Contribution received in Einstein acquisition	-	490,770
(Loss) Gain on investment in acquisitions	(1,410)	175,828
Interest rate hedges	4,923	16,844
Reclassification of net assets	(889)	(2,131)
Net assets released from restrictions used for purchase of property and equipment	4,401	2,318
Decrease in pension liability	151,582	198,830
Distributions to noncontrolling interest	(6,000)	(11,727)
Loss on defeasance of debt	-	(35,808)
Other	361	14
Increase in nonoperating items and other changes in net assets without donor restriction	<u>288,181</u>	<u>460,589</u>
Increase in net assets without donor restriction	<u>\$209,634</u>	<u>\$334,750</u>

The accompanying notes are an integral part of the consolidated financial statements.

Thomas Jefferson University
Consolidated Statements of Changes in Net Assets
For the Years Ended June 30, 2023 and 2022
(In Thousands)

	2023	2022
Net assets without donor restriction:		
Revenues, gains and other support	\$9,700,487	\$7,914,485
Expenses	(9,779,034)	(8,040,324)
Nonoperating items and other changes in net assets without donor restriction, net	<u>288,181</u>	<u>460,589</u>
Increase in net assets without donor restriction	<u>209,634</u>	<u>334,750</u>
Net assets with donor restriction:		
Contributions	115,270	85,240
Gain (Loss) on investments, net	41,186	(52,819)
Net gain (loss) on externally held trusts	8,450	(20,528)
Investment income	7,473	4,757
Net assets released from restrictions	(75,930)	(69,472)
Changes in net assets held by affiliated foundations	2,079	(7,967)
Change in value of split interest agreements	204	(2,285)
Contribution received in Einstein acquisition	-	166,410
Reclassification of net assets	<u>890</u>	<u>2,329</u>
Increase in net assets with donor restriction	<u>99,622</u>	<u>105,665</u>
Increase in net assets	309,256	440,415
Net assets, beginning of year	<u>4,823,333</u>	<u>4,382,918</u>
Net assets, end of year	<u><u>\$5,132,589</u></u>	<u><u>\$4,823,333</u></u>

The accompanying notes are an integral part of the consolidated financial statements.

Thomas Jefferson University
Consolidated Statements of Cash Flows
For the Years Ended June 30, 2023 and 2022
(In Thousands)

	2023	2022
Cash flows from operating activities:		
Increase in net assets	\$309,256	\$440,415
Adjustments to reconcile changes in net assets to net cash provided by (used in) operating activities:		
Value of noncontrolling interest	(28,386)	-
Contributions received in acquisition of Einstein	-	(657,180)
Decrease in pension liability	(151,582)	(198,830)
Depreciation and amortization	359,693	329,355
Bond premium amortization	(11,562)	(9,811)
Change in assets held by affiliated foundation	(2,078)	7,967
(Gain) Loss on investments and other, net	(301,601)	387,770
Gain on investment in acquisitions	(126,553)	(175,828)
Gain on sale of controlling interest	-	(31,620)
Net gain on interest rate hedges	(4,923)	(16,845)
Distribution to noncontrolling interest	6,000	11,727
Funds withheld under the Medicare Accelerated and Advance Payment Program	(129,694)	(368,140)
Loss on defeasance of debt	-	35,808
Contributions designated for acquisition of long-term assets	(37,571)	(37,106)
Net change due to:		
Accounts receivable	(113,038)	(90,754)
Insurance premium receivable	265,124	(308,660)
Pledges receivable	(4,562)	(8,279)
Inventory	631	(7,724)
Accounts payable and accrued expenses	1,160	9,332
Medical costs payable	60,693	(23,548)
DHS insurance program payable	20,306	33,262
Accrued payroll and related costs	(781)	25,489
Grant and contract advances	2,408	37,366
Accrued pension liability	(5,636)	27,644
Insurance recoverable and accrued professional and workers' compensation claims	33,885	(16,441)
Dividends received from joint ventures	3,734	19,563
Other assets and liabilities	(88,544)	(47,844)
Net cash provided by (used in) operating activities	<u>56,379</u>	<u>(632,912)</u>
Cash flows from investing activities:		
Cash received in acquisitions, net	22,096	90,835
Sale of business proceeds	108,000	-
Purchase of land, buildings and equipment	(418,089)	(318,803)
Purchases of investments and assets whose use is limited	(6,673,757)	(9,753,426)
Proceeds from sales of investments and assets whose use is limited	7,342,647	10,049,398
Student loans issued	(3,162)	(3,534)
Student loans repaid	3,485	4,703
Net cash provided by investing activities	<u>381,220</u>	<u>69,173</u>
Cash flows from financing activities:		
Distribution to noncontrolling interest	(6,000)	(11,727)
Contributions designated for acquisition of long-lived assets	37,571	37,106
Federal student loan advances	(223)	(390)
Deferred financing fees	-	(11,029)
Proceeds from revolving line of credit	450,000	-
Repayments from revolving line of credit	(500,000)	-
Proceeds from long-term obligations	-	1,685,672
Repayment of long-term obligations	(79,889)	(1,033,359)
Net cash (used in) provided by financing activities	<u>(98,541)</u>	<u>666,273</u>
Net increase in cash and cash equivalents	339,058	102,534
Cash and cash equivalents at beginning of period	<u>403,988</u>	<u>301,454</u>
Cash and cash equivalents at end of period	<u><u>\$743,046</u></u>	<u><u>\$403,988</u></u>
Supplemental disclosures:		
Interest paid (net of amount capitalized)	\$149,009	\$80,582
Accounts payable related to buildings and equipment	\$72,554	\$47,412
Operating cash flows for operating leases	\$53,765	\$48,755
Right-of-use assets obtained in exchange for lease obligations	\$32,605	\$28,148
Long-term construction obligation	\$141,815	\$165,290

The accompanying notes are an integral part of the consolidated financial statements.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying consolidating financial statements represent the consolidated balance sheets, statements of operations and statements of changes in net assets without donor restrictions and statements of cash flows of Thomas Jefferson University (“TJU”), including TJUH System (“TJUHS”), Abington Health (“Abington”), Jefferson Health Northeast System (“JHNES”), Philadelphia University, Kennedy Health System (“Kennedy”), Magee Rehabilitation Hospital (“Magee”), Albert Einstein Healthcare Network (“Einstein”) and Health Partners Plans (“HPP”).

TJU is an independent, non-profit corporation organized under the laws of the Commonwealth of Pennsylvania (“the Commonwealth”) and recognized as a tax-exempt organization pursuant to Section 501(c) (3) of the Internal Revenue Code. TJU has a tripartite mission of education, research and patient care. TJU conducts research and offers undergraduate and graduate instruction through the Sidney Kimmel Medical College, the Jefferson College of Nursing, the Jefferson College of Pharmacy, the Jefferson College of Health Professions, the Jefferson College of Population Health, the Jefferson College of Biomedical Sciences, the Jefferson College of Rehabilitation Sciences, the Kanbar College of Design, Engineering and Commerce, the School of Continuing and Professional Studies, the College of Architecture and the Built Environment, and the College of Science, Health and the Liberal Arts. TJU has approximately 7,370 students and is located in Philadelphia, Pennsylvania, with additional campus locations in the Greater Philadelphia Region.

TJUHS, Abington, JHNES, Kennedy, Magee and Einstein are integrated healthcare organizations that provide inpatient, outpatient and emergency care services through acute care, ambulatory care, rehabilitation care, physician and other primary care services for residents of the Greater Philadelphia Region. TJU is the sole corporate member of TJUHS, Abington, JHNES, Kennedy, Magee and Einstein.

HPP provides access to healthcare services on a prepaid basis. HPP is licensed by the Commonwealth Departments of Insurance and Health to operate as a Health Maintenance Organization. Pursuant to an agreement effective through August 31, 2022 with the Department of Human Services of the Commonwealth of Pennsylvania (“DHS”), HPP provides for the provision of physical health Medical Assistance (“MA”) Program benefits through its HealthChoices Medicaid Program to enrollees residing in the Southeast Zone (Philadelphia and four surrounding counties – Bucks, Chester, Delaware, and Montgomery). Effective September 1, 2022, HPP entered into the new DHS Expansion contract which covers all HealthChoices zones (Northeast, Northwest, Southeast, Southwest and Lehigh/Capital) in Pennsylvania. Additionally, HPP provides comprehensive physical and behavioral health insurance through the Commonwealth of Pennsylvania’s Children’s Health Insurance Program (CHIP) and its Medicare Advantage program and products through a contract with the Centers for Medicare and Medicaid Services. As of June 30, 2023, there were approximately 371,500, 8,000 and 13,300 members enrolled with Health Partners HealthChoices, CHIP and Medicare programs, respectively. TJU includes the accounts of subsidiaries of Thomas Jefferson University

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

including 1100 Walnut Associates; 925 Walnut Corporation; Jefferson-Solis Mammography Services, LLC; and the accounts of subsidiaries of TJUHS, including Thomas Jefferson University Hospitals, Inc. (“TJUH”); Jefferson University Physicians (“JUP”); Jefferson Physician Services; the Atrium Corporation; Jeffex, Inc.; Methodist Associates in Healthcare, Inc.; JeffCare, Inc.; JeffCare Alliance, LLC; Jefferson University Radiology Associates (“JURA”, an 80% owned joint venture); the Riverview Surgery Center at the Navy Yard, LP (“Riverview”, a 51% owned joint venture); Rothman Orthopaedic Specialty Hospital, LLC (“ROSH”, a 54% owned joint venture); and the accounts of subsidiaries of Abington including Abington Memorial Hospital; Lansdale Hospital Corporation; and Abington Health Foundation; and the accounts of subsidiaries of JHNES including Jefferson Health Northeast (JHNE); Aria Physician Services; Aria Health Orthopaedics; System Service Corporation; Aria IPE, LLC; T.F. Development, Inc.; Health Care, Inc.; TMB Enterprises and Jefferson Health – Northeast Foundation; and the accounts of Philadelphia University; and the accounts of subsidiaries of Kennedy including Kennedy University Hospital, Inc.; Kennedy Health Care Foundation; STAT Medical Transport, Inc.; Kennedy Property Corporation; Kennedy Health Facilities, Inc.; Kennedy Medical Group Practice PC, d/b/a Kennedy Health Alliance; Kennedy Management Group, Inc.; Professional Medical Management Group, Inc.; and the accounts of Magee; and the accounts of subsidiaries of Einstein including Albert Einstein Medical Center; Einstein Practice Plan, Inc.; Einstein Community Health Associates; Einstein Medical Center Montgomery; Montgomery Hospital Center; Fornance Physician Services; BCCT Over Corp; Einstein Healthcare Systems, Inc.; Einstein Care Partners, Inc.; and Broadline Risk Retention Group, Inc.; and the accounts of HPP including SelectScripts, LLC; Health Partners Solutions, LLC and Health Partners Foundation.

Subsequent Events

TJU has performed an evaluation of subsequent events through October 20, 2023, which is the date the consolidated financial statements were issued.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of TJU and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Financial Statement Presentation

The accompanying consolidated financial statements have been prepared on an accrual basis.

TJU classifies net assets as follows:

Net Assets without Donor Restrictions are those assets that are not subject to donor-imposed restrictions and may be expended for any purpose in fulfilling the mission of TJU. These net assets may be used at the discretion of TJU’s management and the Board of Trustees.

Net Assets with Donor Restrictions are those assets whose use by TJU has been limited by donors to a specific time period or purpose. Some donor restrictions are temporary in nature; those restrictions will be met by actions of TJU and/or the passage of time. Other donor

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

restrictions are perpetual in nature, where the funds are to be maintained in perpetuity by TJU, per the stipulation of the donor.

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the consolidated statements of operations and changes in net assets without donor restrictions.

TJU's operating activities within the consolidated statements of operations and changes in net assets without donor restrictions includes revenues and expenses from providing education, research, patient and insurance services, grants and contracts, tuition and fees, unrestricted contributions, net assets released from restriction, government support for Covid-19, distributions of investment returns based on TJU's spending policy and other revenue.

TJU's non-operating activities within the consolidated statements of operations and changes in net assets without donor restrictions include investment returns and other activities related to endowment, contribution received in Einstein transaction, gain and loss on investment in acquisitions, interest rate hedges, net assets released from restrictions used for the purchase of property and equipment value of and distributions to noncontrolling interest, loss on defeasance of debt, reclassification of net assets and long-term benefit plan obligation funding changes that are not part of the TJU's operating activities.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of the financial statements including, but not limited to, recognition of net patient service revenue, which includes implicit price concessions; recognition of estimates for healthcare professional and general liabilities; determination of fair values of certain financial instruments; recognition of medical costs payable and assumptions for measurement of pension obligations. Management relies on historical experience and other assumptions believed to be reasonable relative to the circumstances in making judgments and estimates. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and investments in highly liquid debt instruments with a maturity of three months or less when purchased and are carried at cost, which approximates fair value. All short-term, highly liquid investments, including any such investments purchased with funds on deposit with bond trustees, otherwise qualifying as cash equivalents or restricted cash equivalents, within TJU's investments and assets whose use is limited are treated as investments, at fair value and are therefore excluded from Cash and cash equivalents in the consolidated statements of cash flows.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Short-term investments

Investments classified as short-term investments are available to fund current operations as needed and exclude quasi-endowment funds, donor restricted endowment funds (including beneficial interests in perpetual trusts administered by third parties), investments held under split-interest agreements and investments subject to the equity method.

Charitable Medical Care Provided

TJU provides medically necessary services to all patients regardless of their ability to pay. Some patients qualify for charity care based on policies established by TJU and are therefore not responsible for payment for all or a part of their healthcare services. These policies allow for the provision of free or discounted care in circumstances where requiring payment would impose financial hardship on the patient.

TJU maintains records to identify and monitor the level of charity care provided. These records include the amount of charges foregone for services and supplies furnished. Such amounts have been excluded from net patient service revenue. Management estimates that the cost of charity care provided by TJU was \$41.5 million and \$46.7 million for the years ended June 30, 2023 and 2022, respectively. The estimated costs of providing charity services are based on a calculation which applies a ratio of costs to charges to the gross uncompensated charges associated with providing care to charity patients. The ratio of cost to charges is calculated based on the TJU total expenses divided by gross charges.

Net Patient Service Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which TJU expects to be entitled in exchange for providing patient care.

TJU determines the transaction price based on gross charges for services provided, less contractual adjustments provided to third-party payers based upon agreements, discounts provided to uninsured patients pursuant to TJU's policies, and implicit price concessions provided to uninsured patients and patients with insurance that are responsible for co-pay and/or deductible amounts. TJU determines its estimate of implicit price concessions based upon historical collection experience using a portfolio approach as a practical expedient. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of change.

TJU determines performance obligations based upon the nature of the services provided. Net patient service revenue is recognized as performance obligations are satisfied. TJU recognizes revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations satisfied over time relate to patients in our hospitals receiving inpatient acute care services or patients receiving services in our outpatient centers. TJU measures the performance obligation from admission into the hospital, or the commencement of an outpatient service, to point when there are no further services required for the patient, which is generally at the time of discharge or completion of

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to our patients and customers in a retail setting (for example, pharmaceuticals and medical equipment) and TJU does not believe it is required to provide additional goods or services to the patient.

As substantially all of TJU's patient service performance obligations relate to contracts with a duration of less than one year, TJU has elected to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks after the end of the reporting period.

Net patient service revenue includes estimated retroactive adjustments under reimbursement agreements with third-party payers. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered and are adjusted in future periods as final settlements are determined.

Revenue from the Medicare and Medicaid programs accounted for approximately 42.4% and 17.2%, respectively, and 42.4% and 16.7%, respectively of net patient service revenue in 2023 and 2022, respectively. Most payments to TJU from the Medicare and Medicaid programs for inpatient hospital services are made on a prospective basis. Under these programs, payments are made at a pre-determined specific rate for each discharge based on a patient's diagnosis. Additional payments are made to TJU teaching and disproportionate share hospitals, as well as for cases that have unusually high costs. Laws governing the Medicare and Medicaid programs are complex and subject to interpretation. Services billed to the Medicare program are subject to external review for both medical necessity and billing compliance. Medicare cost reports for all years, except 2011, 2019, 2020, 2021 and 2022 have been audited and final settled as of June 30, 2023. No significant adjustments are expected. In addition, TJU received funds from the Philadelphia Hospital Assessment program and the Medical Assistance Modernization Act-Quality Care Assessment program in the amount of \$313.6 million and \$266.8 million in 2023 and 2022, respectively, and are recorded in net patient service revenue. TJU paid taxes in respect to these programs amounting to \$158.1 million and \$148.7 million in 2023 and 2022, respectively, and are recorded in other operating expenses. Both programs were designed to provide supplemental funding for licensed acute care hospitals with the Philadelphia Hospital Assessment program specifically designated for hospital emergency services.

TJU has also entered into agreements with certain commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for payment to TJU under these agreements includes prospectively determined rates per discharge, discounts from established charges, prospectively determined daily rates and capitated rates. In addition, incentives are paid for high performance with regard to clinical outcome, patient quality, patient satisfaction and efficiency. Revenue from Blue Cross and Aetna USHC amounted to 22.0% and

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

7.1%, respectively, and 23.5% and 8.1%, respectively, of TJU's net patient service revenue in 2023 and 2022, respectively.

Insurance Premium Revenue

Healthcare insurance premiums are recognized as revenue in the month in which the enrollee is entitled to receive health care services and are reported net of an allowance for estimated terminations and uncollectible amounts. Additionally, certain premium revenue subject to the minimum medical loss ratio ("MLR") rebate requirements of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 is recorded net of the estimated minimum MLR rebates. Insurance premium revenue includes MA, Medicare and CHIP contracts.

Medical Costs Payable

Medical costs payable consists principally of unpaid fee-for-service medical and pharmacy claims and capitation costs related to HPP's products. Unpaid healthcare claims include an estimate of payments to be made on claims reported but not yet paid and for healthcare services rendered to members but not yet reported to HPP as of the date of the Consolidated Balance Sheets, collectively, referred to as incurred but not reported (IBNR). Also included in these estimates is the cost of services that will continue to be rendered after the Consolidated Balance Sheets date if HPP is obligated to pay for such services in accordance with contractual or regulatory requirements.

Such estimates are developed using actuarial principles and assumptions which consider, among other things, historical and projected claim submission and processing patterns, assumed and historical medical cost trends, historical utilization of healthcare services, claim inventory levels, changes in membership and product mix, seasonality, and other relevant factors. HPP reflects changes in these estimates in healthcare costs in operating results in the period they are determined. While the ultimate amounts of claims and related expenses are dependent on future developments, it is management's opinion that the liabilities that have been established are adequate to cover such costs.

Grants and Contracts

Grants and contracts revenue primarily represents research activity sponsored by governmental and private sources. TJU's primary source of federal sponsored support is the Department of Health and Human Services. In 2023 and 2022, revenue earned from federal sources totaled \$116.6 million and \$124.9 million, respectively. Facilities and administrative costs recovered on federally sponsored programs are generally based on predetermined rates negotiated with the Federal Government while recovery on all other sponsored projects is based on rates negotiated with the respective sponsor. Funds received for sponsored research activity are subject to audit. Based upon information currently available, management believes that any liability resulting from such audits will not materially affect the consolidated financial position or operations of TJU.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Tuition and Fees

Tuition and fees revenue is recognized in the fiscal year in which the academic programs are delivered. Tuition and fees received in advance of services to be rendered are reported as deferred revenue on the consolidated balance sheets. TJU provides financial aid to eligible students in the form of institutional scholarships, loans and employment during the academic year. Tuition and fees have been reduced by certain institutional grants and scholarships in the amount of \$88.4 million and \$81.7 million in 2023 and 2022, respectively.

Contributions

Contributions, including unconditional promises to donate cash and other assets, are recognized at fair value on the date of receipt, recognized as revenue in the period received and are reported as increases in the appropriate net asset category based on with or without donor restrictions. Pledges received which are to be paid in future periods, and contributions restricted by the donor for specific purposes are reported as net assets with donor restriction support. When a donor restriction expires, that is, when a time restriction ends or stipulated purpose restriction is accomplished, net assets with donor restriction are reclassified to net assets without donor restriction.

Collections

TJU capitalizes works of art, historical treasures, or similar assets (collectively, Collections). Collections are recorded at fair value at the date of the contribution and are not depreciated. Collections of approximately \$5.7 million are included in other noncurrent assets on the consolidated balance sheets at June 30, 2023 and 2022.

Investments

Investments are stated at fair value. The fair value of all debt and equity securities with a readily determinable fair value are based on quotations obtained from national securities exchanges. The alternative investments, which are not readily marketable, are carried at estimated fair values as provided by the investment managers. As a practical expedient, TJU is permitted under the *Fair Value Measurement* standard to estimate the fair value of an investment in an investment company at the measurement date using the reported net asset value (NAV). Adjustment is required if TJU expects to sell the investment at a value other than NAV or if the NAV is not calculated in accordance with US generally accepted accounting principles (US GAAP). TJU's investments are valued based on the most current NAV adjusted for cash flows when the reported NAV is not at the measurement date. This amount represents fair value of these investments at June 30, 2023 and 2022. TJU performs additional procedures including due diligence reviews on its alternative investments and other procedures with respect to the capital account or NAV provided to ensure conformity and compliance with valuation procedures in place, the ability to redeem at NAV at the TJU measurement date and existence of certain redemption restrictions at the measurement date. TJU reviews the values as provided by the investment managers and believes that the carrying amount of these investments is a reasonable estimate of fair value. Because alternative investments are not readily marketable, their estimated values are subject to uncertainty and therefore may differ from the value that would have been used had a ready market for such investments existed.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act (UMIFA) or the Uniform Prudent Management of Institutional Funds Act (UPMIFA). Rather, the Pennsylvania Act governs the investment, use and management of TJU's endowment funds. The Pennsylvania Act allows a nonprofit to elect to appropriate for expenditure an investment policy that seeks the long-term preservation of the real value of the investments. In accordance with the Pennsylvania Act, the objectives of TJU's investment policy is to provide a level of spendable income which is sufficient to meet the current and future budgetary requirements of TJU and which is consistent with the goal of protecting the purchasing power of the investments. As a result of the negative financial impact to nonprofit organizations from COVID-19, the Pennsylvania Act was amended to permit nonprofit organizations to increase the calculation of spendable income from endowment funds from a maximum of 7% up to 10% of the calculated three year average of the endowment market value for fiscal years ending within 2020, 2021 and 2022. For 2023 and 2022, TJU's calculation of spendable income for endowment funds was based on 7% and 10% of a calculated three year average, respectively.

TJU's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and investments. These funds are held in various high-quality financial institutions managed by TJU personnel and outside advisors. TJU maintains its cash and cash equivalents in financial institutions, which at times exceed federally insured limits.

Assets Held by Affiliated Foundations

The Methodist Hospital Foundation ("MHF") and Magee Rehabilitation Hospital Foundation ("MRHF") are separate entities not under the control of TJU. MHF and MRHF accept gifts and bequests and engage in fundraising activities for the benefit of Methodist Hospital and Magee, respectively. The Board of Trustees of MHF and MRHF, at their sole discretion, are authorized to contribute funds to Methodist Hospital and Magee, respectively.

While the sole purpose of MHF and MRHF are to support Methodist Hospital and Magee, this accounting treatment does not imply that MHF and MRHF assets or investment income are those of TJU. The consolidated balance sheets do not reflect or establish the legal relationship, agency or otherwise, between MHF, MRHF and TJU, or any right to assets owned by MHF and MRHF. The by-laws of MHF and MRHF provide that all assets they hold shall not be subject to attachments, execution, or sequestration for any debt, obligation or liability of TJU or any other person or entity. In particular, MHF and MRHF are not party to or obligated by any debt instrument of TJU, and assets owned by MHF and MRHF, are not subject to the lien of any such debt instrument. Underlying investments held by MHF and MRHF with restrictions benefiting only Methodist Hospital and Magee, respectively, are presented in the consolidated balance sheets as follows (in thousands):

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

	<u>2023</u>	<u>2022</u>
Methodist Hospital Foundation	\$11,604	\$11,025
Magee Rehabilitation Hospital Foundation	<u>33,177</u>	<u>31,678</u>
Total	<u>\$44,781</u>	<u>\$42,703</u>

Split Interest Agreements

TJU's split-interest agreements consist of charitable gift annuities, pooled income funds, and charitable remainder trusts. Contribution revenue for charitable gift annuities and charitable remainder trusts is recognized at the date the agreement is established, net of the liability recorded for the present value of the estimated future payments. Contribution revenue for pooled income funds is recognized upon establishment of the agreement at the fair value of the estimated future receipts discounted for the estimated time period to complete the agreement.

Loans Receivable from Students

Many students receive financial aid that consists of scholarship grants, work-study opportunities and student loans. TJU participates in various federal revolving loan programs, in addition to administering institutional loan programs. Student loan programs are funded by donor contributions, other institutional sources, and governmental programs.

The amounts received from the federal government's portion of federal loan programs are ultimately refundable to the federal government and are reported as a liability on TJU's consolidated balance sheets as federal student loan advances. Determination of the fair value of student loans receivable is not practicable.

Student loans receivable, net of allowance for doubtful accounts, consists of the following at June 30, 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Direct student loans, net	\$15,093	\$15,528
Federally-sponsored student loans	<u>4,469</u>	<u>4,357</u>
Total	<u>\$19,562</u>	<u>\$19,885</u>

TJU assesses the adequacy of the allowance for doubtful accounts related to direct student loans receivable by performing evaluations of the student loan portfolio, including a review of the aging of the student loan receivable balances and of the default rate by loan program in comparison to prior years. The level of allowance is adjusted based on the results of this analysis. The federally-sponsored student loans receivable represents amounts due from current and former students under various Federal Government loan programs. For direct student loans it is TJU's policy to reserve 100% of a loan when the loan is delinquent 2 years or more; a reserve of 85% is recorded for loans delinquent more than 270 days and less than 2 years. TJU considers the allowance recorded at June 30, 2023 and 2022 to be reasonable and adequate to absorb potential credit losses inherent in the student loan portfolio.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Land, Buildings, and Equipment, net

Land, buildings, and equipment are carried at cost on the date of acquisition or fair value on the date of donation in the case of gifts. Depreciation expense is computed on a straight-line basis over the estimated useful lives of the assets, excluding land. All gifts of land, buildings, and equipment are recorded as unrestricted non-operating activities unless explicit donor stipulations specify how the donated assets must be used. Interest expense on borrowed funds used for construction, net of interest income earned on unexpended amounts, is capitalized through the completion of construction.

Leases

TJU leases property and equipment under finance and operating leases. TJU determines whether an arrangement is a lease at inception. For leases with terms greater than 12 months, TJU records the related right-of-use (ROU) assets and lease liabilities at the present value of lease payment over the term. The determination of lease payments factors in rental escalation clauses and options to extend or terminate the lease, if the clauses are reasonably certain to be exercised. TJU separates the lease and non-lease components of contracts. TJU's incremental borrowing rate, which is based on information available at the adoption date for existing leases and the commencement date for leases commencing after the adoption date, is used to determine the present value of lease of payments.

Operating leases are included in ROU assets, current portion of operating lease obligations and operating lease obligations on the consolidated balance sheets. Operating lease expense is recognized on the straight-line basis over the lease term and is included in the other operating expense line on the consolidated statements of operations and changes in net assets without donor restrictions.

Finance leases are included in land, buildings and equipment, net, current portion of long term obligations and long term obligations on the consolidated balance sheets. Amortization of finance leases is included in depreciation expense on the consolidated statements of operations and changes in net assets without donor restrictions.

Goodwill

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Any excess of the purchase price over the estimated fair value of the identifiable net assets acquired is recorded as goodwill. The determination of the estimated fair value of net assets acquired requires management's judgment and often involves the use of significant estimates and assumptions.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The change in the carrying amount of goodwill for the year ended June 30, 2023 and 2022 is as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Beginning balance	\$216,140	\$137
Additions	29,969	216,003
Ending balance	<u>\$246,109</u>	<u>\$216,140</u>

Sale of Laboratory Outreach Testing Business

In June 2023, TJU entered into an agreement with an unrelated entity for the sale of TJU's laboratory outreach testing business. The intent of the agreement is to enhance clinical test quality and the efficient and timely delivery of laboratory services for patients and physicians, provide clinical educational opportunities for students, medical residents and fellows and to further the academic and research mission of TJU. TJU recorded a gain on the sale of \$108.0 million included in other revenue in operations.

Sale of Controlling Interest

In June 2022, TJU entered into a joint venture with an unrelated entity to provide home care and hospice services. TJU contributed to the joint venture certain assets used to operate its home health and hospice programs in exchange for a 49% ownership interest. TJU recognized its non-controlling investment in the joint venture at fair value of \$24.1 million and recorded a gain of \$31.7 million included in other revenue in operations.

Reclassifications

Certain amounts in the prior year have been reclassified to conform to the current year presentation.

New Accounting Standards

There were no new accounting standards adopted during the period.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

2. REGULATORY REQUIREMENTS FOR HPP

Commonwealth of Pennsylvania Insurance Law provides that dividends and other distributions may be paid only to the extent of statutory surplus in excess of \$1.5 million as reported in the most recent financial statements filed with the Pennsylvania Insurance Department (PID) and may be paid only out of positive net worth. In addition, legislation requires PID approval of any dividend or other distribution exceeding the greater of (i) 10% of net worth (as of December 31) or (ii) net income for the prior year. The National Association of Insurance Commissioners (NAIC) also requires that insurance companies, including health maintenance organizations, file annually a risk-based capital report to measure the financial health of the entity. DHS also requires HealthChoices contractors to be subject to minimum levels of statutory equity. DHS requires contractors' statutory equity to exceed the highest amounts determined by the following:

- \$20 million;
- 7% of revenue earned by the licensed HMO during the most recent four (4) calendar quarters; and
- 7% of revenue earned by the licensed HMO during the current quarter multiplied by three (3).

With the exception of payments for claims, HealthChoices contractors may not pay or transfer assets to a related party without the prior approval of DHS, if the contractor's statutory equity is less than the minimum stipulated in the HealthChoices contract. In addition to the statutory net worth requirement, the PID has adopted the NAIC Risk-Based Capital (RBC) requirements. RBC is a method of measuring the minimum amount of capital appropriate for a managed care organization to support its overall business operations in consideration of its size and risk profile. The managed care organization's RBC is calculated by applying factors to various asset, premium, and reserve items. The adequacy of a managed care organization's actual capital can then be measured by a comparison to its RBC as determined by the formula. When an organization's net worth falls below 200% of RBC, which is known as the Company Action Level, a company must file a Comprehensive Action Plan with the applicable state regulators describing its plans to increase its net worth above the 200% threshold.

HPP's statutory net worth has exceeded the NAIC Company Action Level calculated for its RBC requirements as of December 31, 2022 and 2021. HPP's recorded capital and surplus under statutory accounting principles was \$258.4 million and \$219.8 million as of December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021 HPP's RBC percentage filed with PID was 381% and 366%, respectively.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

3. BUSINESS COMBINATIONS

Einstein

On October 4, 2021, pursuant to the terms of an integration agreement, TJU became the sole corporate member of Einstein. Einstein is a not for profit healthcare organization located in Pennsylvania. TJU acquired all of the assets and liabilities of Einstein and transferred no consideration. The TJU board was reconstituted to include two voting members and one non-voting member designated by Einstein. This business combination was accounted for as an acquisition. The acquisition of Einstein is intended to enhance access to high quality, cost effective care to the communities served by both organizations and to enhance the educational and research mission of TJU. The following table summarizes the fair value of assets, liabilities and net assets contributed by Einstein at the acquisition date (in thousands):

Cash and cash equivalents	\$91,915
Accounts receivable	125,393
Investments	697,547
Land, buildings and equipment	679,358
Other assets	309,672
Total assets acquired	<u>\$1,903,885</u>
Accrued payroll and related costs	\$64,483
Accrued professional liability and workers' compensation claims	244,660
Long-term obligations	433,671
Accrued pension obligations	180,905
Accounts payable, accrued expenses and other liabilities	322,986
Total liabilities assumed	<u>1,246,705</u>
Net assets without donor restriction	490,770
Net assets with donor restriction	166,410
Total net assets contributed	<u>\$1,903,885</u>

HPP

At June 30, 2021, JHNE held a 25% noncontrolling membership interest in HPP. Additionally, Einstein held a 25% noncontrolling membership interest in HPP when acquired by TJU on October 4, 2021. On November 1, 2021, JHNE purchased the remaining 50% membership interest in HPP for \$305.0 million. The purchase included cash acquired of \$303.9 million and assumed debt of \$7.7 million. JHNE allocated \$112.3 million of the purchase price to certain intangible assets with definite lives. The goodwill of \$214.5 million arising from the acquisition consists of the excess of the estimated aggregate value of HPP over the estimated fair value of the identifiable net assets and existing JHNE and Einstein equity interests. The enterprise value of HPP was estimated using the income approach. The valuation of acquisition date fair value

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

of JHNE and Einstein’s previously held equity noncontrolling interests is based upon their proportionate share of the value of the aggregate equity, The following table summarizes the consideration paid for HPP and the amounts of the assets acquired and liabilities assumed recognized at the acquisition date (in thousands):

Consideration:	
Cash	\$305,000
Fair value of equity interest in HPP held before the acquisition (book value of \$82,450)	<u>258,278</u>
	<u>\$563,278</u>
Recognized amounts of identifiable assets acquired and liabilities assumed:	
Cash	\$303,919
Accounts receivable	171,117
Land, buildings, and equipment	35,211
Investments	120,973
Other assets	42,711
Intangible assets	112,310
Liabilities	<u>(437,465)</u>
	348,776
Goodwill	<u>214,502</u>
	<u>\$563,278</u>

TJU’s pro forma unaudited operating revenues, gains and other support, changes in net assets without donor restriction and changes in net assets with donor restriction for the year ended June 30, 2022, as if the acquisition of Einstein and HPP had occurred at July 1, 2021 are (in thousands):

Operating Revenues, Gains and Other Support	Change in Net Assets Without Donor Restriction	Change in Net Assets With Donor Restriction
<u>\$8,820,006</u>	<u>\$329,317</u>	<u>\$104,783</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

4. NET ASSETS

Net assets consisted of the following at June 30, 2023 and 2022 (in thousands):

Detail of net assets	2023			2022		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Operating	\$2,008,281	\$251,603	\$2,259,884	\$1,932,035	\$259,583	\$2,191,618
Capital gifts	-	96,114	96,114	-	40,152	40,152
Student loan funds	26,262	25,925	52,187	23,602	25,285	48,887
Endowment funds	1,941,531	724,458	2,665,989	1,810,803	676,754	2,487,557
Assets held by affiliated foundations	-	44,781	44,781	-	42,703	42,703
Deferred giving	-	13,634	13,634	-	12,416	12,416
Total	\$3,976,074	\$1,156,515	\$5,132,589	\$3,766,440	\$1,056,893	\$4,823,333

5. ASSETS WHOSE USE IS LIMITED

Assets whose use is limited presented in the consolidated balance sheets at June 30, 2023 and 2022 consist of the following (in thousands):

	2023	2022
Held by trustee under indenture agreement	\$154,937	\$229,778
Designated for insurance	-	136,430
Women's Board and Medical Staff funds	2,263	2,140
Restricted for capital purposes	53,915	32,975
Other	786	2,249
Total	\$211,901	\$403,572
Less current portion	(1,915)	(27,878)
Noncurrent portion	\$209,986	\$375,694

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

6. INVESTMENTS

Investments are presented in the consolidated balance sheets under the following classifications (in thousands):

	<u>2023</u>	<u>2022</u>
Short-term investments	\$860,162	\$1,350,713
Assets whose use is limited, current	1,915	27,878
Long-term investments	2,954,704	2,725,639
Assets whose use is limited, noncurrent	<u>209,986</u>	<u>375,694</u>
	<u>\$4,026,767</u>	<u>\$4,479,924</u>

A summary of investments at June 30, 2023 and 2022 is as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Cash equivalents	\$226,699	\$337,305
Equity securities	40,160	69,196
Fixed income securities	191,599	437,312
Funds:		
Global equity	1,385,110	1,481,296
Fixed income	1,017,868	1,142,349
Real estate	123,202	135,379
Other mutual funds	11,643	13,086
Private equity	581,288	475,402
Real estate	2,263	2,257
Hedge funds	100,321	101,565
External trusts	178,652	170,202
Investments subject to equity method and other	<u>167,962</u>	<u>114,575</u>
	<u>\$4,026,767</u>	<u>\$4,479,924</u>

Most private investment funds (private equity, real asset funds) are structured as closed-end, commitment-based investment funds where TJU commits a specified amount of capital upon inception of the fund (i.e., committed capital) which is then drawn down over a specified period of the fund's life. Such funds generally do not provide redemption options for investors and, subsequent to final closing, do not permit subscriptions by new or existing investors. Accordingly, TJU generally holds interests in such funds for which there is no active market, although in some situations, a transaction may occur in the "secondary market" where an investor purchases a limited partner's existing interest and remaining commitment. The fund managers may value the underlying private investment based on an appraised value, discounted

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

cash flow, industry comparable or some other method. TJU values these limited partnerships at NAV.

Unlike private investment funds, hedge funds are generally open-end funds as they typically offer subscription and redemption options to investors. The frequency of such subscriptions or redemptions is dictated by such fund's governing documents. The amount of liquidity provided to investors in a particular fund is generally consistent with the liquidity and risk associated with the underlying portfolio (i.e., the more liquid the investments in the portfolio, the greater the liquidity provided to the investors). The fund managers invest in a variety of securities which may not be quoted in an active market. Illiquid investments may be valued based on appraised value, discounted cash flow, industry comparable or some other method.

The methods described above may produce a fair value calculation that may not be indicative of a net realized value or reflective of future fair values. Furthermore, while TJU believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

TJU's direct investments in equity and fixed income securities are considered liquid assets because they are traded on established markets with enough participants to absorb sale transactions without materially impacting the current price of the asset. The underlying assets in TJU's investments in equity and fixed income funds are traded on established markets with enough participants to absorb sale transactions without materially impacting the current price. The funds are priced daily and provide next day availability on all transaction requests. TJU's investment in real asset funds provide for monthly liquidity on transaction requests.

Private equity investments have limited liquidity or redemption options. Liquidity for private investments can be accomplished via a secondary sale transaction. When available, distributions typically take place on a quarterly basis. TJU has made commitments to various private equity and real asset limited partnerships. The total amount of unfunded commitments is \$774.8 million and \$646.5 million at June 30, 2023 and 2022, respectively. TJU expects these funds to be called over the next 3 to 5 years (in thousands):

	<u>2023</u>	<u>2022</u>
Private equity	\$774,701	\$646,423
Real estate	<u>81</u>	<u>81</u>
	<u>\$774,782</u>	<u>\$646,504</u>

Hedge funds provide quarterly liquidity with 60 to 90 days' notice prior to the quarter's end limiting TJU's ability to respond quickly to changes in market conditions. Liquidity of individual hedge funds vary based on various factors and may include "gates", "holdbacks" and

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

"side pockets" imposed by the manager of the hedge fund, as well as redemption fees which may also apply. Depending on the redemption options available, it may be possible that the reported NAV represents fair value based on observable data such as ongoing redemption and/or subscription activity. In the cases of a holdback, TJU considers the significance of the holdback, its impact on the overall valuation and the associated risk that the holdback amount will not be fully realized based on a prior history of adjustments to the initially reported NAV.

For those private equity, real estate limited partnerships, or hedge-fund of fund transactions where valuations dated on the last business day of the calendar year are available, the valuations will be based on the most recent capital account statement (monthly/quarterly), adjusted for interim cash flow activity (contributions, distributions, fees).

Beneficial interests in perpetual trusts, which are administered by independent trustees, are mainly comprised of domestic and international equity securities and domestic fixed income securities.

TJU accounts for investments in the following entities under the equity method: Five Pointe Professional Liability Insurance Company ("Five Pointe") (50% owned joint venture insurance entity); Mountain Laurel Risk Retention Group, Inc. ("MLRRG") (50% owned joint venture insurance entity); Delaware Valley Accountable Care Organization ("DVACO") (24.5% and 50% owned joint venture at June 30, 2023 and 2022, respectively); MLJH, LLC (50% owned joint venture); Health Partners Plans ("HPP") (25% membership interest joint venture at June 30, 2021 and a consolidated subsidiary at June 30, 2022 (refer to Note 2 Business Combinations)); Fresenius Medical Care Voorhees, LLC ("FMCV") (30% owned joint venture); JeffHome PA-NJ ("JeffHome") (49% owned joint venture) and Jefferson-Solis Mammography Services, LLC (50% owned joint venture at June 30, 2021 and a consolidated subsidiary at June 30, 2022). A summary of investments subject to the equity method and other investments is as follows at June 30, 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Equity method:		
Five Pointe	\$66,313	\$14,060
MLRRG	5,117	3,481
DVACO, LLC	36	383
MLJH, LLC	31,368	30,553
FMCV, LLC	16,675	13,681
JeffHome, LLC	28,258	24,140
Jefferson-Solis Mammography, LLC	-	9,829
Other equity method investments	7,106	8,953
Other	13,089	9,495
	<u>\$167,962</u>	<u>\$114,575</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

A summary of investments held under split-interest agreements is as follows at June 30, 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Charitable gift annuities	\$14,115	\$13,952
Pooled income funds	590	597
Charitable remainder trusts	<u>8,753</u>	<u>8,545</u>
	<u>\$23,458</u>	<u>\$23,094</u>

Investment income, realized gains (losses) and unrealized gains (losses) included in the consolidated statements of operations and changes in net assets without donor restrictions are comprised of the following in 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Investment income included in operating income (losses):		
Interest and dividends	\$32,437	\$6,778
Endowment payout	134,910	79,527
DVACO	(4,823)	(2,113)
HPP	(318)	5,923
MLJH, LLC	816	1,935
Other joint ventures	<u>877</u>	<u>(3,477)</u>
	\$163,899	88,573
Investment income included in nonoperating income (losses):		
Net realized and unrealized gains (losses)	239,486	(296,466)
Interest and dividends	2,251	1,644
Endowment payout	<u>(134,910)</u>	<u>(79,527)</u>
	<u>106,827</u>	<u>(374,349)</u>
Total	<u>\$270,726</u>	<u>(\$285,776)</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

7. ENDOWMENT FUNDS

TJU's endowments consist of approximately 1,318 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. Net assets associated with each of these groups of funds are classified and reported based upon the existence or absence of donor-imposed restrictions. The University reports all endowment investments at fair value. Cash equivalents in endowments are treated as investments.

At June 30, 2023, the endowment net asset composition by type of fund consisted of the following (in thousands):

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted funds	-	\$724,458	\$724,458
Quasi-endowment funds	\$1,941,530	-	1,941,530
Total funds	<u>\$1,941,530</u>	<u>\$724,458</u>	<u>\$2,665,988</u>

Changes in endowment net assets for the fiscal year ended June 30, 2023, consisted of the following (in thousands):

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$1,810,803	\$676,754	\$2,487,557
Investment returns	168,449	48,310	216,759
Contributions	(4)	18,604	18,600
Appropriation of assets for expenditure	(134,910)	(27,647)	(162,557)
Transfers of University resources and other	97,192	8,437	105,629
Endowment net assets, end of year	<u>\$1,941,530</u>	<u>\$724,458</u>	<u>\$2,665,988</u>

At June 30, 2022, the endowment net asset composition by type of fund consisted of the following (in thousands):

	Without Donor Restriction	With Donor Restriction	Total
Donor-restricted funds	-	\$676,754	\$676,754
Quasi-endowment funds	\$1,810,803	-	1,810,803
Total funds	<u>\$1,810,803</u>	<u>\$676,754</u>	<u>\$2,487,557</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Changes in endowment net assets for the fiscal year ended June 30, 2022, consisted of the following (in thousands):

	Without Donor Restriction	With Donor Restriction	Total
Endowment net assets, beginning of year	\$905,329	\$627,834	\$1,533,163
Investment returns	(68,968)	(71,552)	(140,520)
Contributions	86	20,260	20,346
Acquisition of Einstein	16,529	129,227	145,756
Appropriation of assets for expenditure	(79,527)	(29,277)	(108,804)
Transfers of University resources and other	1,037,354	262	1,037,616
Endowment net assets, end of year	<u>\$1,810,803</u>	<u>\$676,754</u>	<u>\$2,487,557</u>

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor requires TJU to retain as a fund of perpetual duration. Shortfalls of this nature are classified as a reduction of donor-restricted net assets and were \$3.7 million and \$5.4 million as of June 30, 2023 and 2022, respectively. These shortfalls resulted from unfavorable market fluctuations that occurred shortly after the investment of new contributions to endowment and continued appropriation for certain programs that was deemed prudent by TJU.

8. FINANCIAL ASSETS AND LIQUIDITY RESOURCES

TJU's financial assets available within one year of the balance sheet date for general expenditure are as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Financial assets:		
Cash and cash equivalents	\$743,046	\$403,988
Accounts receivable	873,006	761,073
Insurance premium receivable	193,220	479,777
Pledge payments available for operations	14,768	14,344
Short-term investments	767,926	1,273,002
Subsequent year's endowment payout	182,375	156,010
Total financial assets available within one year	<u>2,774,341</u>	<u>3,088,194</u>
Liquidity resources:		
Bank lines of credit	763,200	735,900
Total financial assets and liquidity resources available within one year	<u>\$3,537,541</u>	<u>\$3,824,094</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

TJU's endowment funds consist of donor-restricted and quasi-endowment funds. Income from donor-restricted endowment funds is restricted for specific purposes and therefore, is not available for general expenditures. Although TJU does not intend to spend from its quasi-endowment funds in excess of the endowment payout amount calculated pursuant to its spendable income policy described in Note 1, additional amounts from its quasi-endowment could be made available with Board approval.

As part of TJU's liquidity management, it has a practice to structure its financial assets in a manner to be available to satisfy general expenditures and other obligations as they come due. To manage unanticipated liquidity needs, TJU had available unsecured lines of credit from various banks of \$763.3 million and \$788.0 million at June 30, 2023 and 2022, respectively, under which there was borrowing of \$0.1 million and \$52.1 million at June 30, 2023 and 2022, respectively.

9. FAIR VALUE MEASUREMENT

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

- Level 1 Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that TJU has the ability to access at the measurement date;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;
- Level 3 Inputs that are not currently observable.

Inputs are used in applying the various valuations techniques and broadly refer to the assumption that market participants use to make valuation decisions. An investments level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes "observable" requires significant judgment. The categorization of an investment within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to TJU's perceived risk of that instrument.

Level 1 - Investments, whose values are based on quoted market prices in active markets, are therefore classified within Level 1. Typically, securities traded on the NYSE, AMEX, NASDAQ and other major exchanges will be classified as Level 1. These assets include active listed equities, certain U.S. government obligations, mutual funds and certain money market securities. For investments regularly traded on any recognized securities or commodities exchange, the closing price on such exchange (or, if applicable, as reported on the consolidated transactions reporting system) on the last trading date at the end of the fiscal year is used. In the case of securities regularly traded in the over-the-counter market, the closing bid quotations

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

for long positions and the closing asked quotation for short positions on the trading date ending on or preceding the end of the fiscal year is used.

Level 1 - Liquidity – Daily based on quoted market value at time of transaction or at daily NAV.

Level 2 - Investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. They include investments in common trust equity and fixed income funds, corporate grade bonds, high yield bonds and certain mortgage products. These assets are valued based on quoted market prices in active markets or dealer quotations and are categorized as Level 2. There were no transfers between Levels 1 and 2 during 2023 and 2022.

Level 2 - Liquidity – Daily based on quoted market value at time of transaction or at daily NAV.

Level 3 - Investments classified within Level 3 have significant unobservable inputs, as they trade infrequently or not at all. Level 3 instruments include externally held trust funds.

Level 3 - Liquidity – No liquidity available as the assets are mainly comprised of donor restricted externally held trust funds of which TJU has a perpetual interest in the annual income stream.

The following table presents the short term and long term investments, and assets whose use is limited carried on the consolidated balance sheets by level within the valuation hierarchy or NAV as of June 30, 2023 and 2022 (in thousands):

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>NAV</u>	<u>2023</u>
Cash and cash equivalents	\$226,699	\$0	\$0	\$0	\$226,699
Equity securities	26,045	14,115	-	-	40,160
Fixed income securities	1,102	173,754	-	16,743	191,599
Funds:					
Global equity	30,623	-	-	1,354,488	1,385,111
Fixed income	-	19	-	1,017,849	1,017,868
Real asset	-	4,331	-	118,870	123,201
Other mutual funds	11,643	-	-	-	11,643
Private equity	-	-	-	581,288	581,288
Real estate	-	-	-	2,263	2,263
Hedge funds	-	-	-	100,321	100,321
External trusts	-	-	178,652	-	178,652
Total	<u>\$296,112</u>	<u>\$192,219</u>	<u>\$178,652</u>	<u>\$3,191,822</u>	<u>\$3,858,805</u>
	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>NAV</u>	<u>2022</u>
Cash and cash equivalents	\$311,803	\$25,502	-	-	\$337,305
Equity securities	25,012	13,952	-	\$30,232	69,196
Fixed income securities	10,348	409,992	-	16,972	437,312
Funds:					
Global equity	30,260	-	-	1,451,036	1,481,296
Fixed income	-	19	-	1,142,330	1,142,349
Real asset	-	5,115	-	130,264	135,379
Other mutual funds	13,086	-	-	-	13,086
Private equity	-	-	-	475,402	475,402
Real estate	-	-	-	2,257	2,257
Hedge funds	-	-	-	101,565	101,565
External trusts	-	-	\$170,202	-	170,202
Total	<u>\$390,509</u>	<u>\$454,580</u>	<u>\$170,202</u>	<u>\$3,350,058</u>	<u>\$4,365,349</u>

Investments not subject to fair value leveling or fair value at NAV at June 30, 2023 and 2022 totaled \$168.0 million and \$114.6 million, respectively.

The fair value of TJU's interest rate swaps related to its debt obligations are based on third-party valuations independent of the counterparties. As the fair values of interest rate swaps are determined based on inputs that are readily available or can be derived from information available in public markets, TJU has categorized interest rate swaps as Level 2.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The following table presents the other liabilities carried on the consolidated balance sheets by level within the valuation hierarchy as of June 30, 2023 and 2022 (in thousands):

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>NAV</u>	<u>2023</u>
Interest rate hedges	-	\$11,987	-	-	\$11,987

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>NAV</u>	<u>2022</u>
Interest rate hedges	-	\$18,211	-	-	\$18,211

The following tables include a roll-forward of the amounts for the year ended June 30, 2023 and 2022 (in thousands) for external trust investments classified within Level 3.

	<u>2023</u>	<u>2022</u>
Beginning balance	\$170,202	\$145,052
Unrealized gains/(loss), net	8,450	(30,328)
Contribution received in a business combination	-	56,423
Transfers	-	(945)
Ending balance	<u>\$178,652</u>	<u>\$170,202</u>

10. PLEDGES RECEIVABLE

A summary of pledges receivable is as follows at June 30, 2023 and 2022, respectively (in thousands):

	<u>2023</u>	<u>2022</u>
Unconditional promises expected to be collected in:		
Less than one year	\$41,266	\$25,654
One year to five years	79,741	86,843
Over five years	67,435	71,722
	<u>188,442</u>	<u>184,219</u>
Less: unamortized discount and allowance for doubtful accounts	<u>(35,914)</u>	<u>(36,253)</u>
	<u>\$152,528</u>	<u>\$147,966</u>

The discount rate ranges from 0.0% to 4.0%. TJU's largest pledge comprises 33% and 37% of the pledge receivable at June 30, 2023 and 2022, respectively.

At June 30, 2023, TJU was the recipient of a conditional pledge of \$70.0 million for the construction of a building. This conditional pledge is not included as an asset in the consolidated balance sheets.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

11. LAND, BUILDINGS AND EQUIPMENT

A summary of land, buildings and equipment is as follows at June 30, 2023 and 2022, respectively (in thousands):

	<u>2023</u>	<u>2022</u>
Land and land improvements	\$246,729	\$233,560
Buildings and building improvements	3,866,422	3,836,030
Equipment	2,886,814	2,694,198
Leasehold improvements	179,061	177,508
Construction in progress	775,279	454,434
Less: accumulated depreciation	<u>(3,766,170)</u>	<u>(3,440,779)</u>
Total land, buildings and equipment, net	<u>\$4,188,135</u>	<u>\$3,954,950</u>

TJU uses straight-line depreciation over the assets' estimated lives, which are as follows:

Land improvements	10-20 years
Buildings and building improvements	18-40 years
Equipment	3-15 years
Leasehold improvements	5-20 years

Depreciation expense is \$347.9 million and \$321.2 million at June 30, 2023 and 2022, respectively.

12. MEDICAL CLAIMS PAYABLE

The following table shows the components of the change in medical costs payable for the year ended June 30, 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Medical costs payable June 30, 2022 and November 1, 2021	\$122,670	\$146,218
Claims occurring in:		
Current year	1,787,902	973,253
Prior years	<u>1,287</u>	<u>(6,469)</u>
Net incurred benefit expenses	<u>1,789,189</u>	<u>966,784</u>
Claim payments:		
Current year	(1,506,286)	(860,232)
Prior years	<u>(222,210)</u>	<u>(130,100)</u>
Net payments	<u>(1,728,496)</u>	<u>(990,332)</u>
Medical costs payable June 30, 2023 and 2022	<u>\$183,363</u>	<u>\$122,670</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The positive/(negative) amount noted as “prior year” claims in 2023 and 2022 is unfavorable/favorable development for claim estimates being settled for amounts less than originally anticipated. This unfavorable/ favorable development from original estimates occur due to changes in medical utilization, the mix of provider rates, other components of medical cost trends, and claim payment patterns.

The net incurred medical expense amount for 2023 and 2022 reported above excludes approximately \$164.4 million and \$54.7 million that primarily represents amounts due to contracted risk hospitals.

HPP's estimate of the IBNR liabilities is primarily based on trend and completion factors. Claim frequency is not used in the calculation of its liability.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

13. LONG-TERM OBLIGATIONS

A summary of long-term obligations is as follows at June 30, 2023 and 2022, respectively (in thousands):

	Final Maturity	Interest Rate at June 30, 2023	2023	2022
Revenue bonds:				
Fixed rate obligations:				
2015 Series A Revenue Bonds	2051	3.00% - 5.25%	301,805	\$301,805
Unamortized premium and issue costs			16,705	17,608
2017 Series A Revenue Bonds	2048	3.00% - 5.00%	257,270	257,270
Unamortized premium and issue costs			9,980	10,649
2018 Series A Revenue Bonds	2050	4.00% - 5.00%	341,480	351,835
Unamortized premium and issue costs			17,005	19,322
2018 Series B Revenue Bonds	2030	3.28% - 3.88%	31,470	33,275
Unamortized issue costs			(112)	(145)
2019 Series A Revenue Bonds	2052	4.00% - 5.00%	445,595	449,745
Unamortized premium and issue costs			28,764	32,239
2022 Series A Revenue Bonds	2057	1.725%-3.847%	590,155	590,155
Unamortized issue costs			(4,827)	(4,985)
2022 Series B Revenue Bonds	2057	3.25%-5.00%	672,750	672,750
Unamortized premium and issue costs			73,867	77,235
Total fixed rate obligations			<u>2,781,907</u>	<u>2,808,758</u>
Variable rate obligations:				
2015 Series B Revenue Bonds	2046	2.97%	60,000	60,000
Unamortized issue costs			(420)	(440)
2015 Series C Revenue Bonds	2042	3.54%	31,955	32,825
Unamortized issue costs			(83)	(91)
2015 Series D Revenue Bonds	2042	3.54%	31,725	32,590
Unamortized issue costs			(83)	(91)
2015 Series E Revenue Bonds	2042	3.69%	31,955	32,820
Unamortized issue costs			(83)	(91)
2015 Series F Revenue Bonds	2042	3.69%	31,725	32,590
Unamortized issue costs			(83)	(91)
2015 Series G Revenue Bonds	2042	3.54%	19,060	19,580
Unamortized issue costs			(50)	(54)
2015 Series H Revenue Bonds	2042	4.87%	26,425	27,145
Unamortized issue costs			(72)	(79)
2017 Series B Revenue Bonds	2051	2.97%	50,565	50,565
Unamortized issue costs			(450)	(467)
2017 Series C Revenue Bonds	2051	3.54%	50,000	50,000
Unamortized issue costs			(252)	(262)
2018 Series D Revenue Bonds	2051	2.97%	49,950	49,950
Unamortized issue costs			(369)	(385)
Total variable rate obligations			<u>381,416</u>	<u>386,014</u>
Total Revenue bonds			<u>3,163,322</u>	<u>3,194,772</u>
Line of credit			70	52,092
Finance lease obligations	2037		37,361	28,439
Other			314,963	173,167
Total long-term debt obligations			<u>\$3,515,717</u>	<u>\$3,448,470</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Other long term obligations of \$314.9 million at June 30, 2023 includes \$307.1 million related to a development agreement with an unrelated party for the construction costs related to the core and shell of an ambulatory care facility on land leased by TJU. Construction of the facility is anticipated to be completed in 2024. TJU has the option to purchase or lease the facility.

TJU is a party to the Amended and Restated Master Trust Indenture (the “MTI”), dated as of February 1, 2022, by and among TJU, each other Member of the Obligated Group (as described below) and Master Trustee. The MTI provides for the issuance from time to time of obligations.

To secure its payment obligations under the MTI, each Member of the Obligated Group has granted to the Master Trustee for the equal and ratable benefit of the holders of all obligations issued and outstanding under the MTI (other than subordinated obligations) a first lien on and security interest in the gross revenues of each Member of the Obligated Group on a joint and several basis.

The Members of the Obligated Group consist of the following: TJU, TJUHS, TJUH, JUP, Abington Health, Abington Memorial Hospital, Abington Health Foundation, Lansdale Hospital, Jefferson Health-Northeast System, Jefferson Health-Northeast, Philadelphia University, Kennedy Health System, Kennedy Health Facilities, Inc., Kennedy University Hospital, Inc., Kennedy Medical Group Practice, PC, Magee, Albert Einstein Health Network, Albert Einstein Medical Center, Einstein Community Health Associates, Inc., Einstein Medical Center Montgomery, Einstein Practice Plan, Inc., Fornance Physician Services, Montgomery Hospital, and Montgomery Health Foundation.

TJU and each other Member of the Obligated Group have agreed to comply with certain financial and operational covenants contained in the MTI, certain continuing covenant agreements (the “CCAs”) associated with several series of bonds as well as a standby letter of credit agreement (the SBLOC”) and a revolving credit agreement (the “Revolver”, and collectively with the CCAs and the SBLOC, the “Credit Agreements”). TJU was in compliance with the covenants in the MTI and Credit Agreements at June 30, 2023.

The Series 2022A and 2022B Revenue Bonds were issued in February 2022. The proceeds were used to fund the costs of (i) certain capital projects, (ii) the acquisition by TJU of a membership interest in Albert Einstein Health Network related to the payment or defeasance in whole of certain indebtedness previously issued for the benefit of Albert Einstein Health Network, (iii) repayment of draws on TJU’s lines of credit, the proceeds of which were used by Jefferson Health – Northeast for the acquisition of the remaining interest in Health Partners Plans, and (iv) refunding the Series A of 2012, Series 2012, Series 2017A stated to mature on September 1, 2040 and September 1, 2042, and Series 2018C.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Maturities for long-term debt are as follows (in thousands):

	<u>Revenue Bonds and Other</u>	<u>Finance Lease Obligations</u>	<u>Total</u>
2024	333,878	11,008	344,886
2025	36,935	10,115	47,050
2026	32,195	7,679	39,874
2027	35,210	4,545	39,755
2028	38,850	2,884	41,734
Thereafter	2,861,781	1,131	2,862,912

14. DERIVATIVE FINANCIAL INSTRUMENTS

TJU entered into derivative transactions for the purpose of reducing the impact of fluctuations in interest rates and hedging interest rate risk. The fair value of these derivative instruments at June 30, 2023 and 2022 in the consolidated balance sheets is as follows (in thousands):

Expiration Date	TJU Receives	TJU Pays	Notional Amount at June 30, 2023	Notional Amount at June 30, 2022	Balance Sheet Location	Fair Value at June 30, 2023	Fair Value at June 30, 2022
Expiration 2/1/34	67% of United States Dollar LIBOR (one Month)	2.98%	\$57,180	\$60,650	Noncurrent Liability	(\$732)	\$1,176
Expiration 9/1/45	67% of United States Dollar LIBOR (one Month)	3.925%	\$38,643	\$32,900	Noncurrent Liability	\$11,272	\$15,296
Expiration 5/1/27	68% of United States Dollar LIBOR (one Month)	3.98%	\$20,600	\$25,225	Noncurrent Liability	\$403	\$1,383
Expiration 5/1/27	68% of United States Dollar LIBOR (Five Year minus 0.293%)	68% of United States Dollar LIBOR (one Month)	\$35,825	\$43,900	Noncurrent Liability	\$654	\$212
Expiration 5/1/27	68% of United States Dollar LIBOR (Five Year minus 0.325%)	68% of United States Dollar LIBOR (one Month)	\$20,600	\$25,225	Noncurrent Liability	\$391	\$145

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The LIBOR with a one-month maturity ranged from 1.78% to 5.22% (average rate of 4.01%) in 2023. The LIBOR rate with the five-year maturity ranged from 2.67% to 4.49% (average rate of 3.74%) in 2023. Non-operating gains of \$4.9 million and \$16.8 million at June 30, 2023 and 2022, respectively, are included in the consolidated statements of operations and changes in net assets without donor restrictions for interest rate swap contracts (in thousands).

	<u>2023</u>	<u>2022</u>
Change in valuation of interest rate hedges	\$6,224	\$16,708
Net settlement payments with counterparties	<u>(1,301)</u>	<u>137</u>
Nonoperating gain (loss) on interest rate hedges	<u>\$4,923</u>	<u>\$16,845</u>

Accumulated losses on interest rate hedges of \$12.0 million and \$18.2 million at June 30, 2023 and 2022, respectively, are reflected in the consolidated balance sheets.

15. LEASE COMMITMENTS

TJU has operating lease obligations primarily for ambulatory facilities, office space and land expiring through 2099. The components of lease expense was as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Amount of rent expense related to amortization of right-of-use assets	\$58,442	\$59,047
Short-term and variable lease costs	<u>44,762</u>	<u>35,556</u>
Rent expense	<u>\$103,204</u>	<u>\$94,603</u>
Weighted average remaining lease term (years)	11.7	12.2
Weighted average discount rate	2.64%	2.52%

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

A summary of future minimum commitments under operating leases, at June 30, 2023, is as follows (in thousands):

2024	\$59,141
2025	55,530
2026	49,374
2027	42,382
2028	37,936
Thereafter	<u>173,965</u>
Total minimum lease payments	<u>418,328</u>
Less imputed interest	<u>(56,819)</u>
Net present value of minimum lease payments	<u><u>\$361,509</u></u>

Future minimum lease payments at June 30, 2022 were as follows (in thousands):

2023	\$60,648
2024	56,579
2025	53,939
2026	47,449
2027	40,738
Thereafter	205,777
Total minimum lease payments	<u>465,130</u>
Less imputed interest	<u>(63,259)</u>
Net present value of minimum lease payments	<u><u>\$401,871</u></u>

16. EMPLOYEE BENEFIT PLANS

TJU has non-contributory defined benefit pension plans for certain full-time employees. The TJU plan is frozen new entrants and the Einstein plan is not. Benefits under the non-contributory defined benefit plans are based on the employee's years of service and compensation during the years preceding retirement. Contributions to the plan are designed to meet the minimum funding requirements of the Employee Retirement Income Security Act of 1974.

The accounting guidance for defined benefit pension plans requires employers to recognize the overfunded or underfunded projected benefit obligation ("PBO") of a defined benefit pension plan as an asset or liability in the balance sheet. The PBO represents the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future salary increases. The accounting guidance also requires employers to recognize annual changes in gains or losses, prior service costs, or other credits that have not been recognized as

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

a component of net periodic pension cost through net assets without donor restriction. The calculation of service cost and PBO utilizes a split discount rate approach, where separate discount rates are calculated for determining each based on their respective expected cash flows.

The components of the net pension plan financial position on the consolidated balance sheets are as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$2,574,572	\$2,403,325
Acquisition	-	763,057
Service cost	45,009	49,775
Interest cost	112,680	70,249
Net experience gain	(100,418)	(614,682)
Benefits paid	<u>(160,023)</u>	<u>(97,152)</u>
Projected benefit obligation, end of year	2,471,820	2,574,572
Change in plan assets:		
Fair value of plan assets, beginning of year	2,173,461	2,011,933
Acquisition	-	582,152
Actual return of plan assets	163,845	(345,604)
Employer contributions	50,644	22,132
Benefit payments	<u>(160,023)</u>	<u>(97,152)</u>
Fair value of plan assets, end of year	<u>2,227,927</u>	<u>2,173,461</u>
Plan funded status	<u><u>(\$243,893)</u></u>	<u><u>(\$401,111)</u></u>

Amounts recognized in net assets without donor restriction consist of (in thousands):

	<u>2023</u>	<u>2022</u>
Net actuarial loss	\$81,650	\$230,941
Net unrecognized prior service costs	<u>(7,216)</u>	<u>(8,511)</u>
	<u><u>\$74,434</u></u>	<u><u>\$222,430</u></u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The accumulated benefit obligation at June 30, 2023 and 2022 was as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Accumulated benefit obligation	<u>\$2,346,668</u>	<u>\$2,455,480</u>

The components of net periodic benefit cost for the plans for the years ended June 30, 2023 and 2022 were as follows (in thousands):

	<u>2023</u>	<u>2022</u>
Service cost	\$45,009	\$49,775
Interest cost	112,680	70,249
Expected return on plan assets	(127,810)	(146,260)
Amortization of actuarial loss	7,903	16,273
Amortization of prior service credit	<u>(1,295)</u>	<u>(1,295)</u>
Net periodic benefit cost (credit)	36,487	(11,258)
Other changes in plan assets and benefit obligations recognized in net assets without donor restriction:		
Net actuarial gain	(136,452)	(122,818)
Amortization of net actuarial loss	(7,903)	(16,273)
Amortization of prior service credit	<u>1,295</u>	<u>1,295</u>
Total recognized in net assets without donor restriction	(143,060)	(137,796)
Total recognized in net periodic benefit cost and net assets without donor restriction	<u>(\$106,573)</u>	<u>(\$149,054)</u>

There will be no estimated actuarial loss that will be amortized from net assets without donor restriction during the upcoming fiscal year.

The weighted average assumptions used to estimate the June 30 pension obligation were as follows:

	<u>2023</u>	<u>2022</u>
Discount rate	5.18%	4.83%
Rate of compensation increase	1.50% to 4.50%	1.50% to 4.50%
Expected return on plan assets	6.74%	6.09%

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The weighted average assumptions used to determine net periodic benefit costs were as follows:

	<u>2023</u>	<u>2022</u>
Discount rate - service cost	4.93%	3.37%
Discount rate - interest cost	4.50%	2.39%
Rate of compensation increase	1.50% to 4.75%	1.50% to 4.75%
Expected return on plan assets	6.09%	6.05%

A summary of the plans' targeted and actual asset allocations are as follows:

	<u>Targeted Range</u>	<u>Percentage of Plan Assets June 30, 2023</u>	<u>Percentage of Plan Assets June 30, 2022</u>
Cash	0-5%	2%	5%
Bonds	25-45%	32%	33%
Global equity	45-65%	56%	52%
Real estate and other	5-10%	10%	10%
		<u>100%</u>	<u>100%</u>

The portfolios utilize a long-term asset allocation strategy that allows management to rebalance the asset allocation back to target levels on a monthly basis. Short-term compliance with the target ranges can be impacted by the severity of market conditions. The expected long-term rate of return for the plan's assets are based on the historical return of each of the above categories, weighted based on the target allocations for each class. The assets of the defined benefit pension plan are invested in a manner that is intended to preserve the purchasing power of the plan's assets and provide payments to beneficiaries. Thus, a rate of return objective of inflation plus 5% is targeted.

TJU expects to contribute approximately \$53.0 million during fiscal year 2024.

Projected benefit payments are as follows (in thousands):

2024	\$148,781
2025	135,203
2026	142,621
2027	150,239
2028	156,498
Thereafter	<u>852,289</u>
	<u>\$1,585,631</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The following table presents the fair value of plan assets by level within the valuation hierarchy, as discussed in Note 8, as of June 30, 2023 and 2022 (in thousands):

	Level 1	Level 2	Level 3	NAV	2023
Cash and cash equivalents	\$5,286	\$45,890	-	-	\$51,176
Equity securities	(355)	-	-	-	(355)
Fixed income securities	-	1	-	-	1
Global equity	-	-	-	\$1,242,361	1,242,361
Fixed income	-	-	-	708,863	708,863
Real assets	-	-	-	116,071	116,071
Other mutual funds	-	-	-	-	-
Private equity	-	-	-	83,769	83,769
Hedge funds	-	-	-	26,041	26,041
Total	<u>\$4,931</u>	<u>\$45,891</u>	<u>-</u>	<u>2,177,105</u>	<u>\$2,227,927</u>

	Level 1	Level 2	Level 3	NAV	2022
Cash and cash equivalents	\$69,333	\$44,203	\$1,206	-	\$114,742
Equity securities	1,957	-	-	-	1,957
Fixed income securities	-	1	-	-	1
Global equity	-	-	-	1,113,181	1,113,181
Fixed income	21	-	-	727,478	727,499
Real assets	-	-	-	116,335	116,335
Other mutual funds	-	-	-	-	-
Private equity	-	-	-	73,469	73,469
Hedge funds	-	-	-	26,277	26,277
Total	<u>\$71,311</u>	<u>\$44,204</u>	<u>\$1,206</u>	<u>2,056,740</u>	<u>\$2,173,461</u>

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Retirement benefits are also provided to certain employees through direct payments to various funds. Employees not subject to TJU's defined benefit plans may be eligible to participate in one of the following defined contribution arrangements. TJU's share of the cost of these benefits for the year ended June 30, 2023 and 2022 was as follows (in thousands):

Plan	Description	2023	2022
TJU: Faculty and senior administrators	9% to 13% of eligible compensation based upon age	\$27,371	\$13,090
TJU: Non-faculty and non-union	4.5% of eligible compensation, plus matching contribution of 25% of the first 6% of employee contributions	35,499	17,239
JUP	10% of eligible compensation for physicians and 3.5% to 5.5% of eligible compensation for non-physicians based upon years of service	24,387	12,642
Abington	2% to 5% of eligible compensation based upon years of service, plus matching contribution of 50% of the first \$2,000 of employee contributions	9,260	5,296
JHNES	Matching contribution of 50% of the first 4% of employee contributions plus 1% to 7% based on age and years of service	15,415	4,733
Philadelphia University	9% of eligible compensation	2,797	1,478
Kennedy	Matching contribution of 50% to 100% of the first 4% of employee contributions starting in year 3. For those that started after 7/1/15, another 2.75% to 4.75% of their annual salary in lieu of a defined benefit plan	8,672	4,096
Magee	2% to 4% of eligible compensation, plus matching contribution of 25% of the first 6% of employee contributions	2,064	1,148
HPP	4% of eligible compensation, plus matching contribution of 100% of the first 3% of employee contributions and 50% of employee contributions greater than 3% up to a maximum of 5%	5,155	3,294
Einstein	For Philadelphia employees earning less than \$100,000, a matching contribution of 20%, up to 4% of pay, with an annual maximum of \$400. For Montgomery County employees, a matching contribution of 50%, up to 2.5% of salary.	6,585	2,773
		\$137,205	\$65,789

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Participation in Multiemployer Defined Benefit Pension Plan

TJU is a participating employer in The Pension Fund for Hospital and Health Care Employees – Philadelphia and Vicinity (the Pension Fund), a jointly-trusted multiemployer defined benefit pension plan. The Pension Fund is operated for the benefit of Chapter 1199C of the American Federation of State, County and Municipal Employees (the Union). Information about the Pension Fund and the TJU’s participation is summarized as follows.

The employer identification number for the Pension Fund is 23-2627428. At the date the consolidated financial statements were issued Form 5500 was not available for the plan year ending in 2022. TJU’s contribution to the Pension Fund was \$7.3 million and \$7.1 million for the years ended June 30, 2023 and 2022. The contributions represent approximately 18.0% and 31.0% of the contributions to the Pension Fund, respectively. A five year collective bargaining agreement was approved by the Union effective July 1, 2022 and extends through June 30, 2027. TJU contributions as a percentage of covered payroll to the Pension Fund for the year ending June 30, 2023 will be 21.6 %.

The Pension Fund was determined to be in critical status (also referred to as red zone status) under the Pension Protection Act of 2006 for the plan years beginning January 1, 2022 and 2021. Accordingly, the Pension Fund is subject to a funding improvement plan. The zone status is based on information that TJU received from the plan and is certified by the plan’s actuary. Among other factors, plans in the red zone status are generally less than 65% funded.

At January 1, 2022, the most recent date for which such information is available the projected benefit obligation exceeded plan assets of the Pension Fund by \$266.7 million.

17. PROFESSIONAL LIABILITY CLAIMS

TJU maintains professional liability insurance under both self-insured and alternative risk financing insurance programs to fund for their potential professional and general liability claims. For all self-insured programs TJU accrues for estimated retained risk liability arising from both asserted and unasserted claims. The estimate of liability is based upon an analysis of historical claims data as prepared by independent actuaries.

For Einstein, Kennedy, Magee, TJU and TJUHS, including JUP the primary layer of professional liability coverage is provided by MLRRG. MLRRG is a licensed captive insurance company qualified as a risk retention group domiciled in Vermont. TJU is a 50% owner of MLRRG. The remaining ownership interest is held by another regional healthcare system. MLRRG is reinsured by a non-profit 501(c) (3) segregated protected cell insurance company, Five Pointe, domiciled in Delaware. Five Pointe reinsures 100% of the professional liability risks insured by MLRRG pursuant to a reinsurance agreement between Five Pointe and MLRRG that limits MLRRG’s recourse for payment of any reinsured claims against Einstein, Kennedy, Magee, TJU, JUP and/or TJUHS to the assets in the TJUH protected cell.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

For Abington and JHNES the primary layer of professional liability coverage is provided by Cassatt RRG (“CRRG”). CRRG is a licensed captive insurance company qualified as a risk retention group domiciled in Vermont. CRRG is owned and governed by various regional non-profit hospitals including a 25% voting interest by Abington and a 25% voting interest by JHNES. CRRG is reinsured by Cassatt Insurance Company Ltd. (“CICL”). CICL is owned by the same various regional non-profit hospitals and is incorporated as an insurance company under the laws of Bermuda.

Pennsylvania’s Medical Care Availability and Reduction of Error Fund (the “MCARE Fund”) provides limits excess of the primary layer of coverage. The annual assessments for MCARE Fund coverage are based on the schedule of occurrence rates approved by the Insurance Commissioner of Pennsylvania for the Pennsylvania Professional Liability Joint Underwriting Association multiplied by an annual assessment percentage. This assessment is recognized as an expense in the period incurred. No provision has been made for future MCARE Fund assessments as the unfunded portion of the MCARE Fund liability cannot be reasonably estimated.

For losses in excess of the primary and MCARE layers of coverage TJU accrues for potential liabilities for self-insured amounts. Additionally, TJU maintains claims-made excess catastrophic professional liability insurance coverage through Five Pointe and CICL. For excess layer coverage purchased through CICL, coverage limits are shared with the various regional non-profit hospital owners of CRRG and CICL. Five Pointe and CICL purchase reinsurance with commercial carriers rated at least “A-“ by AM Best.

For MLRRG the premiums charged for the primary professional layer of coverage are determined by an independent actuary, based on loss and loss adjustment expense experience and other factors, at a 65% confidence level and a 3% discount rate for 2023 and 2022 and include a charge for premium tax and operating expenses.

For CRRG and CICL the premiums charged for the primary professional layer of coverage are determined by an independent actuary, based on loss and loss adjustment expense experience and other factors, at an expected confidence interval and a 3.5% discount rate for 2023 and 2022.

TJU has accrued professional liability claims of \$886.6 million and \$850.9 million at June 30, 2023 and 2022, respectively, of which \$223.3 million and \$234.4 million were current. TJU records accrued professional liability claims for self-insured exposures at an expected confidence interval and a 3.0% to 3.5% discount rate.

TJU records anticipated malpractice insurance recoveries and associated accrued professional liability claims at a 65% confidence level (TJUHS, Kennedy, Magee and Einstein) and an expected level (Abington and JHNES) using discount rate from 3.0% to 3.5%. Anticipated malpractice insurance recoveries for June 30, 2023 and 2022 is \$443.0 million and \$378.3 million, respectively.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

18. WORKERS' COMPENSATION CLAIMS

TJU is self-insured for its workers' compensation exposures. TJU accrues for its workers' compensation liability based upon actuarial estimates using a discount rate of 3%. Accrued workers' compensation liabilities were \$44.0 million and \$46.4 million at June 30, 2023 and 2022, respectively. These amounts are presented in the accompanying consolidated balance sheets.

19. COMMITMENTS AND CONTINGENCIES

Letters of Credit

TJU had open letters of credit aggregating \$10.5 million and \$68.9 million at June 30, 2023 and 2022, respectively, primarily related to self-insurance arrangements for workers' compensation. The letters of credit expire between November 1, 2023 and December 31, 2024.

Litigation

TJU is involved in litigation and regulatory investigations arising in the ordinary course of business. In the opinion of management, all such matters are adequately covered by commercial insurance or by accruals, and if not so covered, are without merit or are of such kind, or involve such amounts, as would not have a material adverse effect on the consolidated financial position or results of operations of TJU.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

20. FUNCTIONAL CLASSIFICATION

Expenses for the years ended June 30, 2023 and 2022 are categorized on a functional basis as follows (in thousands):

	2023				
	Education and Research	Clinical Operations	Insurance	General, Administrative, Operations and Maintenance	Total
Salaries and wages	\$281,710	\$3,015,329	\$88,427	\$365,686	\$3,751,152
Employee benefits	\$69,623	\$711,636	\$19,686	\$83,584	884,529
Insurance services medical expenses	-	-	1,593,742	-	1,593,742
Supplies	24,986	1,322,886	-	9,564	1,357,436
Purchased services	45,456	501,153	56,441	252,897	855,947
Depreciation and amortization	36,848	303,300	16,947	1,472	358,567
Interest	14,345	94,335	891	6,835	116,406
Insurance	1,868	156,948	1,398	35	160,249
Utilities	8,692	55,693	1,384	4,740	70,509
Other expenses	43,739	170,527	5,871	410,360	630,497
Total	\$527,267	\$6,331,807	\$1,784,787	\$1,135,173	\$9,779,034

	2022				
	Education and Research	Clinical Operations	Insurance	General, Administrative, Operations and Maintenance	Total
Salaries and wages	\$266,941	\$2,685,158	51,714	\$311,961	\$3,315,774
Employee benefits	58,158	561,624	12,392	94,435	726,609
Insurance services medical expenses	-	-	862,277	-	862,277
Supplies	32,998	1,179,871	-	9,571	1,222,440
Purchased services	41,788	482,525	29,636	196,116	750,065
Depreciation and amortization	39,139	277,453	10,481	1,230	328,303
Interest	13,584	69,848	540	23	83,995
Insurance	2,990	131,293	1,133	788	136,204
Utilities	10,274	57,620	727	5,361	73,982
Other expenses	56,798	233,117	4,124	246,636	540,675
Total	\$522,670	\$5,678,509	973,024	\$866,121	\$8,040,324

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

21. NONCONTROLLING INTEREST

TJU has a controlling interest in certain joint ventures in healthcare related organizations; Riverview, a 51% owned joint venture; JURA, an 80% owned joint venture and ROSH, a 54% owned joint venture and Jefferson-Solis Mammography Services, LLC, a 60% owned joint venture. The amount not owned by TJU is shown as a non-controlling interest. The following table presents the changes in consolidated net assets without donor restriction attributable to the controlling financial interest of TJU and the non-controlling interest (in thousands):

	Controlling Interest	Non-controlling Interest	Consolidated Total
Balance, June 30, 2021	\$3,414,189	\$17,501	\$3,431,690
Income from Operations	(133,023)	7,184	(125,839)
Distributions to NCI	-	(11,727)	(11,727)
Other changes, net	472,316	-	472,316
Balance, June 30, 2022	<u>\$3,753,482</u>	<u>\$12,958</u>	<u>\$3,766,440</u>
Income from Operations	(85,855)	7,308	(78,547)
Distributions to NCI	-	(6,000)	(6,000)
Other changes, net	265,795	28,386	294,181
Balance, June 30, 2023	<u>\$3,933,422</u>	<u>\$42,652</u>	<u>\$3,976,074</u>

22. GOVERNMENT SUPPORT

The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law on March 27, 2020 to provide economic relief to individuals and organizations from the effects of COVID-19. The CARES Act included the following key provisions impacting TJU:

Provider Relief Fund - provided general funding to providers that participated in the Medicare and Medicaid programs and targeted funding to providers in areas particularly impacted by the COVID-19 outbreak and hospitals that treated a high volume of COVID-19 admissions.

Higher Education Emergency Relief Fund – provided funding to higher education institutions for certain costs incurred or amounts refunded to students related to cessation of housing and dining services due to COVID-19. Additionally, \$5.1 million of the funding received by TJU in 2022 was required to be paid directly to currently enrolled students in the form of emergency grants.

Employee Retention Credit - provided funding to eligible employers in the form of a refundable tax credit on qualifying wages paid to employees during a period of government shut-down due to the COVID-19 pandemic.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Disaster Relief Fund - provided additional funding to the Federal Emergency Management Agency (FEMA) and Pennsylvania Emergency Management Agency (PEMA) to support medical providers for the costs of treating COVID-19 patients.

The following table summarizes the amounts recognized as revenue from government support for COVID-19 in the accompanying consolidated statements of operations and changes in net assets without donor restrictions for June 30, 2023 and 2022 (in thousands):

	<u>2023</u>	<u>2022</u>
Provider Relief Fund	\$16,000	\$88,294
Higher Education Emergency Relief	658	9,649
Employee Retention Credit	-	(2,580)
Disaster Relief (FEMA/PEMA)	31,926	24,000
Total	<u>\$48,584</u>	<u>\$119,363</u>

Revenue recognition of government support for COVID-19 was based upon substantially satisfying all terms and conditions related to the applicable awards. Significant terms and conditions included that payments will only be reimbursement for health care or educational related expenses or lost revenue attributable to COVID-19 and limitations on billing patients for deductibles and coinsurance.

TJU recognized revenue related to the CARES Act provider relief funding based on information contained in laws and regulations, as well as interpretations issued by the Department of Health and Human Services (HHS), governing the funding that was publicly available at June 30, 2023. HHS has made multiple changes to its guidance during the COVID-19 pandemic. The potential financial impacts of future changes in guidance may impact TJU's ability to retain some or all of the distributions received.

Accrued receivables of \$16.3 million and \$18.9 million are included in the accompanying consolidated balance sheets for the years ended June 30, 2023 and 2022 related to the Employee Retention Credit.

Additionally, the CARES act included a provision for deferring payment of the employer portion of social security taxes that would be otherwise due between March 27, 2020 and December 31, 2020. The law permitted payment of these taxes to be extended to December 31, 2021 for 50% of the amount due and December 31, 2022 for the remaining 50%. At June 30, 2023, TJU had no remaining liability for these taxes.

Thomas Jefferson University
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

24. ADVANCES

The Centers for Medicare & Medicaid Services (CMS) established the CMS Accelerated and Advance Payment (CMSAAP) program to increase the cash flow to Medicare providers impacted by COVID-19. The following table presents the CMSAAP liability included in the advances line item in the accompanying consolidated balance sheets (in thousands):

Balance, June 30, 2021	395,391
Acquisition of Einstein	102,513
Repayments	<u>(368,140)</u>
Balance, June 30, 2022	\$129,764
Repayments	<u>(129,694)</u>
Balance, June 30, 2023	<u><u>\$70</u></u>

Schedule of Expenditures of Federal Awards

Thomas Jefferson University

Schedule of Expenditures of Federal Awards

June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Student Financial Aid Cluster							
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
Nursing Student Loans							
Outstanding loans as of June 30, 2023	93.364	2,259,817	-			2,259,817	-
New loans issued during 2023	93.364	451,666	-			451,666	-
		<u>2,711,483</u>	<u>-</u>			<u>2,711,483</u>	<u>-</u>
Nurse Faculty Loan Program							
New loans issued during 2023	93.264	190,641	-			190,641	-
		<u>190,641</u>	<u>-</u>			<u>190,641</u>	<u>-</u>
Health Professions Student Loans, Including Primary Care Loans/Loans for Disadvantaged Students							
Outstanding loans as of June 30, 2023	93.342	873,916	-			873,916	-
New loans issued during 2023	93.342	124,000	-			124,000	-
		<u>997,916</u>	<u>-</u>			<u>997,916</u>	<u>-</u>
		<u>3,900,040</u>	<u>-</u>			<u>3,900,040</u>	<u>-</u>
Total Department of Health and Human Services							
DEPARTMENT OF EDUCATION							
Federal Supplemental Educational Opportunity Grants							
Federal Supplemental Educational Opportunity Grants	84.007	18,831	-			18,831	-
Administrative Cost Allowance	84.007	1,102,752	-			1,102,752	-
Federal Work-Study Program							
Federal Work-Study Program	84.033	4,108	-			4,108	-
Federal Work-Study Program	84.033	(158,570)	-			(158,570)	-
Federal Work-Study Program	84.033	296,785	-			296,785	-
Federal Work-Study Program	84.033	952,306	-			952,306	-
Federal Pell Grant Program	84.063	6,679,462	-			6,679,462	-
Federal Perkins Loans							
Outstanding loans as of June 30, 2023	84.038	1,754,265	-			1,754,265	-
New loans issued during 2023	84.038	-	-			-	-
Federal Direct Student Loans	84.268	122,814,545	-			122,814,545	-
		<u>133,464,484</u>	<u>-</u>			<u>133,464,484</u>	<u>-</u>
		<u>\$ 137,364,524</u>	<u>\$ -</u>			<u>\$ 137,364,524</u>	<u>\$ -</u>
TOTAL STUDENT FINANCIAL AID CLUSTER							
Education Stabilization Fund							
Total Education Stabilization Fund	84.425F	1,405,739	-			1,405,739	-
		<u>\$ 1,405,739</u>	<u>\$ -</u>			<u>\$ 1,405,739</u>	<u>\$ -</u>
		<u>\$ 134,870,223</u>	<u>\$ -</u>			<u>\$ 134,870,223</u>	<u>\$ -</u>
Total Department of Education							
Research and Development Cluster							
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
National Institutes of Health							
Environmental Health	93.113	83,842	-			83,842	-
Environmental Health	93.113	(2,228)	-			(2,228)	-
Environmental Health	93.113	542,678	-			542,678	40,624
Environmental Health	93.113	106,836	-			106,836	-
Environmental Health	93.113	282,959	-			282,959	-
Environmental Health	93.113	194,132	-			194,132	-
Environmental Health	93.113	20,017	-			20,017	-
Environmental Health	93.113	2,645	-			2,645	-
Environmental Health	93.113	-	4,029	Colorado State University	R01ES030937	4,029	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Oral Diseases and Disorders Research	93-121	(0)	-			(0)	-
Oral Diseases and Disorders Research	93-121	79,599	-			79,599	-
Oral Diseases and Disorders Research	93-121	35,968	-			35,968	-
Oral Diseases and Disorders Research	93-121	68,093	-			68,093	-
Oral Diseases and Disorders Research	93-121	-	8,811	SINTX Technologies Corporation	R43DE031456	8,811	-
Oral Diseases and Disorders Research	93-121	-	(212)	Temple University	263777-TJU	(212)	-
Human Genome Research	93-172	31,621	-			31,621	-
Human Genome Research	93-172	240,617	-			240,617	-
Human Genome Research	93-172	-	267,317	Foundation for Applied Molecular Evo.	R01HG011669	267,317	-
Human Genome Research	93-172	-	57,440	The Jackson Laboratory	U24HG011735	57,440	-
Human Genome Research	93-172	-	1,787	The Jackson Laboratory	U24HG011735-03	1,787	-
Human Genome Research	93-172	-	20,089	The Jackson Laboratory	R01HG010679	20,089	-
Research Related to Deafness and Communication Disorders	93-173	283,606	-			283,606	-
Research Related to Deafness and Communication Disorders	93-173	158,943	-			158,943	-
Research Related to Deafness and Communication Disorders	93-173	-	10,536	Monell Chemical Senses Center	R01DC018042	10,536	-
Research Related to Deafness and Communication Disorders	93-173	-	140,071	The George Washington University	18-S15	140,071	-
Research Related to Deafness and Communication Disorders	93-173	49,871	-			49,871	-
Research Related to Deafness and Communication Disorders	93-173	-	14,287	The University of Alabama at Birmingham	000524835-SC001	14,287	-
Mental Health Research Grants	93-242	775,942	-			775,942	213,836
Mental Health Research Grants	93-242	119,073	-			119,073	-
Mental Health Research Grants	93-242	-	18,128	Virginia Polytechnic Institute	R34MH129785	18,128	-
Mental Health Research Grants	93-242	-	0	University Of North Carolina At Chapel	U01MH110925	0	-
Alcohol Research Programs	93-273	110,664	-			110,664	-
Alcohol Research Programs	93-273	481,827	-			481,827	56,442
Alcohol Research Programs	93-273	332	-			332	-
Alcohol Research Programs	93-273	338,101	-			338,101	-
Alcohol Research Programs	93-273	40,452	-			40,452	-
Alcohol Research Programs	93-273	-	69,606	University Of Colorado, Denver	R21AA028871	69,606	-
Alcohol Research Programs	93-273	-	6,560	University Of Colorado, Denver	R24AA019661	6,560	-
Alcohol Research Programs	93-273	-	(121)	Univ of Louisville Res Found, Inc.	P50AA024337	(121)	-
Alcohol Research Programs	93-273	-	4,398	Univ of Louisville Res Found, Inc.	P50AA024337	4,398	-
Drug Abuse and Addiction Research Programs	93-279	288,313	-			288,313	-
Drug Abuse and Addiction Research Programs	93-279	353,416	-			353,416	-
Drug Abuse and Addiction Research Programs	93-279	3,507	-			3,507	-
Drug Abuse and Addiction Research Programs	93-279	14,059	-			14,059	-
Drug Abuse and Addiction Research Programs	93-279	9,021	-			9,021	-
Drug Abuse and Addiction Research Programs	93-279	-	65,021	Temple University	R01DA054921	65,021	-
Drug Abuse and Addiction Research Programs	93-279	-	(34)	RTM Vital Signs, LLC.	R41DA047779	(34)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	80,285	-			80,285	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	16,409	-			16,409	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	324,679	-			324,679	315,783
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	(1,186)	-			(1,186)	-
Discovery and Applied Research for Technological Innovations to Improve Human Health	93-286	378,099	-			378,099	122,668
Minority Health and Health Disparities Research	93-307	-	2,219	University of CA, Irvine	R01MD12778	2,219	-
Trans-NIH Research Support	93-310	412,533	-			412,533	244,691
Trans-NIH Research Support	93-310	-	7,504	Emory University	OT2OD030535	7,504	-
Trans-NIH Research Support	93-310	-	24,683	Nemours Foundation	UG1OD024958	24,683	-
Research Infrastructure Programs	93-351	1,969,275	-			1,969,275	-
Research Infrastructure Programs	93-351	397,553	-			397,553	-
Research Infrastructure Programs	93-351	246,128	-			246,128	-
Research Infrastructure Programs	93-351	-	148,192	University of Pittsburgh	P40OD010996	148,192	-
Research Infrastructure Programs	93-351	-	14,417	University of Pittsburgh	P40OD010996	14,417	-
21st Century Cures Act - Beau Biden Cancer Moonshot	93-353	-	13,952	The Trustees of The University of PA	U01CA243702	13,952	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Nursing Research	93.361	-	122,246	Villanova University	R01NR018655	122,246	-
Nursing Research	93.361	-	23,179	The Trustees of The University of PA	R01NR019753	23,179	-
Nursing Research	93.361	-	(834)	Columbia University	R01NR016865	(834)	-
Nursing Research	93.361	-	28,346	Columbia University	R01NR016865	28,346	-
Cancer Cause and Prevention Research	93.393	(2,793)	-			(2,793)	-
Cancer Cause and Prevention Research	93.393	1,467	-			1,467	-
Cancer Cause and Prevention Research	93.393	168,736	-			168,736	1,154
Cancer Cause and Prevention Research	93.393	64,496	-			64,496	-
Cancer Cause and Prevention Research	93.393	19,038	-			19,038	-
Cancer Cause and Prevention Research	93.393	28,188	-			28,188	(42,103)
Cancer Cause and Prevention Research	93.393	256,500	-			256,500	-
Cancer Cause and Prevention Research	93.393	199,943	-			199,943	-
Cancer Cause and Prevention Research	93.393	362,285	-			362,285	150,728
Cancer Cause and Prevention Research	93.393	-	18,110	The Trustees of The University of PA	R01CA190871	18,110	-
Cancer Cause and Prevention Research	93.393	-	14,448	Mayo Clinic	R01CA237398	14,448	-
Cancer Cause and Prevention Research	93.393	-	5,499	University of Arizona	690141	5,499	-
Cancer Cause and Prevention Research	93.393	-	(788)	Northwestern University	R01CA218436	(788)	-
Cancer Cause and Prevention Research	93.393	-	82,097	University Of Delaware	R01CA194178	82,097	-
Cancer Cause and Prevention Research	93.393	-	29,750	University of Arkansas	R01CA229324	29,750	-
Cancer Detection and Diagnosis Research	93.394	217,760	-			217,760	35,332
Cancer Detection and Diagnosis Research	93.394	(8,559)	-			(8,559)	-
Cancer Detection and Diagnosis Research	93.394	342	-			342	-
Cancer Detection and Diagnosis Research	93.394	243,532	-			243,532	-
Cancer Detection and Diagnosis Research	93.394	1,803	-			1,803	-
Cancer Detection and Diagnosis Research	93.394	18,326	-			18,326	-
Cancer Detection and Diagnosis Research	93.394	409,602	-			409,602	114,053
Cancer Detection and Diagnosis Research	93.394	423,192	-			423,192	116,626
Cancer Detection and Diagnosis Research	93.394	511,408	-			511,408	312,816
Cancer Detection and Diagnosis Research	93.394	683,934	-			683,934	-
Cancer Detection and Diagnosis Research	93.394	17,077	-			17,077	-
Cancer Detection and Diagnosis Research	93.394	14,273	-			14,273	-
Cancer Detection and Diagnosis Research	93.394	253,343	-			253,343	79,352
Cancer Detection and Diagnosis Research	93.394	307,085	-			307,085	103,873
Cancer Detection and Diagnosis Research	93.394	147,493	-			147,493	-
Cancer Detection and Diagnosis Research	93.394	687,187	-			687,187	93,221
Cancer Detection and Diagnosis Research	93.394	42,958	-			42,958	-
Cancer Detection and Diagnosis Research	93.394	38,865	-			38,865	-
Cancer Detection and Diagnosis Research	93.394	171,593	-			171,593	-
Cancer Detection and Diagnosis Research	93.394	208,910	-			208,910	-
Cancer Detection and Diagnosis Research	93.394	-	134,998	Minnesota Department of Health	NU50CK000563	134,998	-
Cancer Detection and Diagnosis Research	93.394	-	23,351	Medical College Of Wisconsin	R03CA259594	23,351	-
Cancer Detection and Diagnosis Research	93.394	-	52,174	The Trustees of The University of PA	R01CA269948	52,174	-
Cancer Detection and Diagnosis Research	93.394	-	(121)	Baruch S. Blumberg Institute	R01CA202769	(121)	-
Cancer Detection and Diagnosis Research	93.394	-	3,958	JBS Science, Inc.	R44CA165312-TJU	3,958	-
Cancer Detection and Diagnosis Research	93.394	-	5,277	Drexel University	R21CA252933	5,277	-
Cancer Treatment Research	93.395	16,158	-			16,158	-
Cancer Treatment Research	93.395	12,633	-			12,633	-
Cancer Treatment Research	93.395	292,207	-			292,207	-
Cancer Treatment Research	93.395	432,747	-			432,747	-
Cancer Treatment Research	93.395	255,307	-			255,307	-
Cancer Treatment Research	93.395	122,630	-			122,630	-
Cancer Treatment Research	93.395	344,701	-			344,701	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Cancer Treatment Research	93.395	97,790	-			97,790	-
Cancer Treatment Research	93.395	5,519	-			5,519	-
Cancer Treatment Research	93.395	555,925	-			555,925	107,922
Cancer Treatment Research	93.395	200,839	-			200,839	-
Cancer Treatment Research	93.395	306,258	-			306,258	-
Cancer Treatment Research	93.395	44,399	-			44,399	-
Cancer Treatment Research	93.395	38,774	-			38,774	-
Cancer Treatment Research	93.395	476,142	-			476,142	266,583
Cancer Treatment Research	93.395	160,887	-			160,887	-
Cancer Treatment Research	93.395	139,993	-			139,993	-
Cancer Treatment Research	93.395	3,649	-			3,649	-
Cancer Treatment Research	93.395	254,644	-			254,644	-
Cancer Treatment Research	93.395	125,354	-			125,354	-
Cancer Treatment Research	93.395	30,919	-			30,919	-
Cancer Treatment Research	93.395	-	158,147	The Reg of the Univ. of CA, San Diego	R01CA257505	158,147	-
Cancer Treatment Research	93.395	-	3,955	NRG Oncology Foundation	U10CA180868	3,955	-
Cancer Treatment Research	93.395	-	102,542	Lehigh University	R21CA267087	102,542	-
Cancer Treatment Research	93.395	-	173,253	The Trustees of The University of PA	R01CA270483	173,253	-
Cancer Treatment Research	93.395	-	18,692	VA Commonwealth University	R21CA259969	18,692	-
Cancer Treatment Research	93.395	-	125,656	Wistar Institute	R01CA272645	125,656	-
Cancer Treatment Research	93.395	-	25,643	Medical College Of Wisconsin	R01CA267549	25,643	-
Cancer Treatment Research	93.395	-	29,118	Frontier Science And Technology Research	N/A	29,118	-
Cancer Treatment Research	93.395	-	15,078	NRG Oncology Foundation	U10CA180868	15,078	-
Cancer Treatment Research	93.395	-	14,752	NRG Oncology Foundation	U10CA180868	14,752	-
Cancer Treatment Research	93.395	-	55,115	NRG Oncology Foundation	U10CA180868	55,115	37,380
Cancer Treatment Research	93.395	-	19,697	ECOG-ACRIN Medical Research Foundation	U10CA180820	19,697	-
Cancer Treatment Research	93.395	-	19,427	ECOG-ACRIN Medical Research Foundation	U10CA180820	19,427	-
Cancer Treatment Research	93.395	-	19,391	ECOG-ACRIN Medical Research Foundation	5UG1CA189828	19,391	-
Cancer Treatment Research	93.395	-	(1,873)	Johns Hopkins University	UM1CA186691	(1,873)	-
Cancer Treatment Research	93.395	-	5,328	Johns Hopkins University	UM1CA186691	5,328	-
Cancer Treatment Research	93.395	-	4,905	ECOG-ACRIN Cancer Research Group	F30CA189433	4,905	-
Cancer Treatment Research	93.395	-	(32)	Bound Therapeutics, LLC.	R41CA235707	(32)	-
Cancer Treatment Research	93.395	-	4,529	NRG Oncology Foundation	U10CA180868	4,529	-
Cancer Treatment Research	93.395	-	170,284	Wistar Institute	P01CA114046	170,284	-
Cancer Treatment Research	93.395	-	31,314	University Of Virginia	R01CA214594	31,314	-
Cancer Treatment Research	93.395	-	39,087	Arizona State University	R15CA249617	39,087	-
Cancer Treatment Research	93.395	-	19,075	Recombination Therapeutics, LLC	R41CA257002	19,075	-
Cancer Biology Research	93.396	83,062	-			83,062	-
Cancer Biology Research	93.396	182,779	-			182,779	-
Cancer Biology Research	93.396	230,459	-			230,459	-
Cancer Biology Research	93.396	369,248	-			369,248	-
Cancer Biology Research	93.396	305,414	-			305,414	-
Cancer Biology Research	93.396	39,257	-			39,257	-
Cancer Biology Research	93.396	654,586	-			654,586	157,689
Cancer Biology Research	93.396	363,898	-			363,898	-
Cancer Biology Research	93.396	435,414	-			435,414	-
Cancer Biology Research	93.396	46,353	-			46,353	-
Cancer Biology Research	93.396	606,762	-			606,762	247,681
Cancer Biology Research	93.396	74,927	-			74,927	-
Cancer Biology Research	93.396	295,552	-			295,552	-
Cancer Biology Research	93.396	176,243	-			176,243	-
Cancer Biology Research	93.396	265,110	-			265,110	-
Cancer Biology Research	93.396	311,300	-			311,300	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Cancer Biology Research	93.396	-	5,193	Mayo Clinic	Ro1CA261925	5,193	-
Cancer Biology Research	93.396	-	9,410	Wistar Institute	Po1CA140043	9,410	-
Cancer Biology Research	93.396	-	14,668	Wistar Institute	Po1CA140043	14,668	-
Cancer Biology Research	93.396	-	46,238	Temple University	Ro1CA244179	46,238	-
Cancer Centers Support Grants	93.397	324,328	-			324,328	-
Cancer Centers Support Grants	93.397	268,242	-			268,242	-
Cancer Centers Support Grants	93.397	146,459	-			146,459	-
Cancer Centers Support Grants	93.397	15,518	-			15,518	18,080
Cancer Centers Support Grants	93.397	508,406	-			508,406	-
Cancer Centers Support Grants	93.397	202,874	-			202,874	-
Cancer Centers Support Grants	93.397	311,379	-			311,379	-
Cancer Centers Support Grants	93.397	115,364	-			115,364	-
Cancer Centers Support Grants	93.397	100,356	-			100,356	-
Cancer Centers Support Grants	93.397	303,788	-			303,788	-
Cancer Centers Support Grants	93.397	96,002	-			96,002	-
Cancer Centers Support Grants	93.397	76,718	-			76,718	-
Cancer Centers Support Grants	93.397	(175)	-			(175)	-
Cancer Centers Support Grants	93.397	72,407	-			72,407	-
Cancer Centers Support Grants	93.397	35,532	-			35,532	-
Cancer Centers Support Grants	93.397	155	-			155	-
Cancer Centers Support Grants	93.397	37,813	-			37,813	-
Cancer Centers Support Grants	93.397	(830)	-			(830)	-
Cancer Centers Support Grants	93.397	108,913	-			108,913	62,184
Cancer Centers Support Grants	93.397	76,514	-			76,514	-
Cancer Centers Support Grants	93.397	78,904	-			78,904	-
Cancer Centers Support Grants	93.397	84,407	-			84,407	-
Cancer Centers Support Grants	93.397	2,304	-			2,304	-
Cancer Centers Support Grants	93.397	-	82,710	University Of Maryland, Baltimore	U54CA273956	82,710	-
Cancer Centers Support Grants	93.397	-	(14)	Dana-Farber Cancer Institute	P2oCA233255	(14)	-
Cancer Research Manpower	93.398	316,095	-			316,095	-
Cancer Research Manpower	93.398	42,287	-			42,287	-
Cancer Research Manpower	93.398	6,109	-			6,109	-
Cancer Research Manpower	93.398	129,810	-			129,810	-
Cancer Research Manpower	93.398	95,346	-			95,346	-
Cancer Research Manpower	93.398	41,483	-			41,483	-
Cancer Research Manpower	93.398	41,930	-			41,930	-
Cancer Control	93.399	-	63,119	University of Wisconsin	UG1CA245635	63,119	-
Cancer Control	93.399	-	7,161	University of Wisconsin	UG1CA245635	7,161	-
Cancer Control	93.399	-	8	Frontier Science And Technology Research	N/A	8	-
Cancer Control	93.399	-	15,476	Frontier Science And Technology Research	N/A	15,476	-
Cancer Control	93.399	-	38,827	ECOG-ACRIN Medical Research Foundation	UG1CA189828	38,827	-
Cancer Control	93.399	-	13,956	ECOG-ACRIN Medical Research Foundation	UG1CA189828	13,956	-
Cardiovascular Diseases Research	93.837	307,198	-			307,198	1,706
Cardiovascular Diseases Research	93.837	390,462	-			390,462	13,741
Cardiovascular Diseases Research	93.837	168,843	-			168,843	222,141
Cardiovascular Diseases Research	93.837	270,871	-			270,871	-
Cardiovascular Diseases Research	93.837	245,727	-			245,727	-
Cardiovascular Diseases Research	93.837	122,955	-			122,955	-
Cardiovascular Diseases Research	93.837	49,850	-			49,850	-
Cardiovascular Diseases Research	93.837	267,775	-			267,775	99,244
Cardiovascular Diseases Research	93.837	(1,447)	-			(1,447)	-
Cardiovascular Diseases Research	93.837	99,237	-			99,237	-
Cardiovascular Diseases Research	93.837	79,722	-			79,722	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Cardiovascular Diseases Research	93.837	51,441	-			51,441	20,840
Cardiovascular Diseases Research	93.837	127,004	-			127,004	3,968
Cardiovascular Diseases Research	93.837	271,232	-			271,232	52,516
Cardiovascular Diseases Research	93.837	430,369	-			430,369	1,777
Cardiovascular Diseases Research	93.837	122,925	-			122,925	14,325
Cardiovascular Diseases Research	93.837	159,321	-			159,321	86,042
Cardiovascular Diseases Research	93.837	193,950	-			193,950	-
Cardiovascular Diseases Research	93.837	129,396	-			129,396	-
Cardiovascular Diseases Research	93.837	-	59,369	Albert Einstein Healthcare Network	R01HL159062	59,369	-
Cardiovascular Diseases Research	93.837	-	17,685	Drexel University	R01HL163666-01	17,685	-
Cardiovascular Diseases Research	93.837	-	61,050	Fox Chase Chemical Diversity Center, Inc	R44HL123126	61,050	-
Cardiovascular Diseases Research	93.837	-	2,154	Yale University	U01HL125511	2,154	-
Cardiovascular Diseases Research	93.837	-	11,553	Yale University	U01HL125511	11,553	-
Cardiovascular Diseases Research	93.837	-	610	Duke University	U01HL134679	610	-
Cardiovascular Diseases Research	93.837	-	96,112	The OH State University	R01HL142588	96,112	-
Cardiovascular Diseases Research	93.837	-	9,971	University of Pittsburgh	UG3HL145269	9,971	-
Cardiovascular Diseases Research	93.837	-	67,523	Icahn School of Medicine at Mount Sinai	R01HL141841	67,523	-
Lung Diseases Research	93.838	374,381	-			374,381	191,475
Lung Diseases Research	93.838	412	-			412	-
Lung Diseases Research	93.838	174,109	-			174,109	22,635
Lung Diseases Research	93.838	258,628	-			258,628	-
Lung Diseases Research	93.838	427,735	-			427,735	186,625
Lung Diseases Research	93.838	43,090	-			43,090	-
Lung Diseases Research	93.838	354,958	-			354,958	163,130
Lung Diseases Research	93.838	399,250	-			399,250	-
Lung Diseases Research	93.838	237,554	-			237,554	-
Lung Diseases Research	93.838	209,830	-			209,830	-
Lung Diseases Research	93.838	460,745	-			460,745	13,683
Lung Diseases Research	93.838	355,049	-			355,049	-
Lung Diseases Research	93.838	-	8,718	The Trustees of The University of PA	K23HL151879	8,718	-
Lung Diseases Research	93.838	-	(2,572)	The Trustees of The University of PA	K23HL151879	(2,572)	-
Lung Diseases Research	93.838	-	74,549	Rutgers University	P01HL114471	74,549	-
Lung Diseases Research	93.838	-	28,016	Rutgers University	P01HL114471	28,016	-
Lung Diseases Research	93.838	-	179,711	Rutgers University	P01HL114471	179,711	-
Lung Diseases Research	93.838	-	46,062	Rutgers University	P01HL114471	46,062	-
Lung Diseases Research	93.838	-	133,454	Rutgers University	P01HL114471	133,454	84,382
Lung Diseases Research	93.838	-	155,115	Rutgers University	P01HL114471	155,115	-
Lung Diseases Research	93.838	-	77,136	Rutgers University	P01HL114471	77,136	-
Lung Diseases Research	93.838	-	18,171	Rutgers University	P01HL114471	18,171	-
Lung Diseases Research	93.838	-	325,754	Rutgers University	P01HL114471	325,754	-
Lung Diseases Research	93.838	-	59,825	Rutgers University	P01HL114471	59,825	-
Lung Diseases Research	93.838	-	1,851	University Of Alabama at Birmingham	U01HL133232	1,851	-
Blood Diseases and Resources Research	93.839	433,517	-			433,517	-
Blood Diseases and Resources Research	93.839	452,388	-			452,388	-
Blood Diseases and Resources Research	93.839	320,795	-			320,795	-
Blood Diseases and Resources Research	93.839	611,115	-			611,115	-
Blood Diseases and Resources Research	93.839	102,610	-			102,610	-
Blood Diseases and Resources Research	93.839	380,298	-			380,298	-
Blood Diseases and Resources Research	93.839	-	25,802	Molecular Targeting Technologies, Inc.	R41HL167303	25,802	-
Blood Diseases and Resources Research	93.839	-	12,347	Rutgers University	U01HL133817	12,347	-
Blood Diseases and Resources Research	93.839	-	73,813	University Of Utah	R01HL141424	73,813	-
Blood Diseases and Resources Research	93.839	-	10,920	Temple University	R01HL137376	10,920	-
Blood Diseases and Resources Research	93.839	-	9,337	Temple University	R01HL109568	9,337	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Blood Diseases and Resources Research	93.839	-	3,334	Washington University	UH3HL138325	3,334	-
Blood Diseases and Resources Research	93.839	-	9,896	The Trustees of The University of PA	Ro1HL148014	9,896	-
Blood Diseases and Resources Research	93.839	-	316,831	The Children's Hospital Of Philadelphia	Po1HL139420	316,831	-
Blood Diseases and Resources Research	93.839	-	(5,262)	University Of Kentucky	R35HL150818	(5,262)	-
Blood Diseases and Resources Research	93.839	-	52,051	University Of Kentucky	R35HL150818	52,051	-
Blood Diseases and Resources Research	93.839	-	106,602	The Trustees of The University of PA	Po1HL146373	106,602	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	24,983	-			24,983	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	617,760	-			617,760	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	2,276	-			2,276	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	338,371	-			338,371	108,192
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	260,946	-			260,946	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	326,847	-			326,847	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	465,331	-			465,331	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	336,112	-			336,112	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	421,824	-			421,824	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	20,542	-			20,542	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	448,283	-			448,283	150,091
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	50,094	-			50,094	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	262,196	-			262,196	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	140,160	-			140,160	19,750
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	547,922	-			547,922	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	166,875	-			166,875	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	76,408	-			76,408	29,123
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	135,614	-			135,614	-
Arthritis, Musculoskeletal and Skin Diseases Research	93.846	52,832	-			52,832	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	39,890	-			39,890	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	1,250	-			1,250	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	25,464	-			25,464	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	362,376	-			362,376	97,688
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	273,056	-			273,056	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	168,006	-			168,006	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	137,161	-			137,161	41,870
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	187,092	-			187,092	19,722
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	342,163	-			342,163	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	537,394	-			537,394	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	582,932	-			582,932	273,266
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	315,252	-			315,252	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	299,740	-			299,740	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	203,038	-			203,038	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	252,668	-			252,668	10,793
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	385,604	Duke University	5Uo1DKo83027-15	385,604	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	49,847	-			49,847	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	57,895	-			57,895	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	258	Albert Einstein Healthcare Network	Uo1DKo83027	258	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	9,853	Columbia University	Uo1DK116066	9,853	-
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	-	29,882	Duke University	2037923	29,882	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	274,281	-			274,281	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	405,418	-			405,418	110,683
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	35,108	-			35,108	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	2,231	-			2,231	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	190,555	-			190,555	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	517,358	-			517,358	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	330,186	-			330,186	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	347,694	-			347,694	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	1	-			1	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	172,639	-			172,639	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	195,546	-			195,546	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	67,890	-			67,890	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	289,925	-			289,925	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	519,086	-			519,086	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	295,661	-			295,661	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	516,117	-			516,117	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	4,965	-			4,965	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	548,801	-			548,801	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	585,926	-			585,926	244,176
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	481,056	-			481,056	15,494
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	487,240	-			487,240	211,597
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	378,287	-			378,287	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	7,011	-			7,011	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	370,296	-			370,296	43,387
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	178,969	-			178,969	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	60,072	-			60,072	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	40,147	-			40,147	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	567,494	-			567,494	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	185,620	-			185,620	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	485,193	-			485,193	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	357,380	-			357,380	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	454,729	-			454,729	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	34,084	-			34,084	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	375,529	-			375,529	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	233,957	-			233,957	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	151,070	-			151,070	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	141,534	-			141,534	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	129,359	-			129,359	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	65,581	-			65,581	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	336,618	-			336,618	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	21,716	-			21,716	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	46,619	-			46,619	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	43,525	-			43,525	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	15,437	-			15,437	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	14,886	Temple University	RF1NS121379	14,886	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	130	University of Cincinnati	U01NS106513	130	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	29,731	Case Western Reserve University	UH3NS103863	29,731	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	10,225	Cleveland Clinic Lerner College Of Medic	U01NS100610	10,225	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	5,195	University Of Texas, Southwestern Medica	P01NS097197	5,195	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	43,958	University of Pittsburgh	U01NS099046	43,958	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	78,478	The Trustees of The University of PA	R01NS106611	78,478	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	52	Trustees Of The University Of Pennsylvan	U01NS113198	52	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,201	University of Cincinnati	U01NS102289	1,201	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,306	University of Cincinnati	U01NS102289	1,306	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	1,123	University of Cincinnati	U01NS106513	1,123	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	13,959	University of Cincinnati	U01NS095869	13,959	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	42,597	Columbia University	R01NS114122	42,597	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	26,860	University of Cincinnati Coordinating Center	012358-138467	26,860	-
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	113,675	Kessler Foundation Inc.	40611-02	113,675	17,578
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	20,207	Ohio State University	GR125940 SPC-100006037	20,207	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853	-	53,312	Ohio State University	GR128742	53,312	-
Allergy and Infectious Diseases Research	93.855	52,018	-			52,018	-
Allergy and Infectious Diseases Research	93.855	104,127	-			104,127	-
Allergy and Infectious Diseases Research	93.855	57,869	-			57,869	-
Allergy and Infectious Diseases Research	93.855	162,659	-			162,659	-
Allergy and Infectious Diseases Research	93.855	92,736	-			92,736	-
Allergy and Infectious Diseases Research	93.855	27,200	-			27,200	-
Allergy and Infectious Diseases Research	93.855	61,800	-			61,800	-
Allergy and Infectious Diseases Research	93.855	32,643	-			32,643	-
Allergy and Infectious Diseases Research	93.855	388,815	-			388,815	-
Allergy and Infectious Diseases Research	93.855	6,489	-			6,489	2,042
Allergy and Infectious Diseases Research	93.855	378,535	-			378,535	-
Allergy and Infectious Diseases Research	93.855	209,219	-			209,219	27,878
Allergy and Infectious Diseases Research	93.855	(2,073)	-			(2,073)	-
Allergy and Infectious Diseases Research	93.855	6,992	-			6,992	-
Allergy and Infectious Diseases Research	93.855	400,654	-			400,654	-
Allergy and Infectious Diseases Research	93.855	561,518	-			561,518	298,468
Allergy and Infectious Diseases Research	93.855	516,070	-			516,070	-
Allergy and Infectious Diseases Research	93.855	441,832	-			441,832	-
Allergy and Infectious Diseases Research	93.855	519,346	-			519,346	-
Allergy and Infectious Diseases Research	93.855	257,875	-			257,875	-
Allergy and Infectious Diseases Research	93.855	171,550	-			171,550	-
Allergy and Infectious Diseases Research	93.855	70,264	-			70,264	-
Allergy and Infectious Diseases Research	93.855	67,832	-			67,832	-
Allergy and Infectious Diseases Research	93.855	236,698	-			236,698	-
Allergy and Infectious Diseases Research	93.855	469,423	-			469,423	-
Allergy and Infectious Diseases Research	93.855	148,677	-			148,677	-
Allergy and Infectious Diseases Research	93.855	100,151	-			100,151	-
Allergy and Infectious Diseases Research	93.855	358,053	-			358,053	-
Allergy and Infectious Diseases Research	93.855	120,754	-			120,754	38,801
Allergy and Infectious Diseases Research	93.855	245,333	-			245,333	-
Allergy and Infectious Diseases Research	93.855	258,868	-			258,868	647
Allergy and Infectious Diseases Research	93.855	123,242	-			123,242	-
Allergy and Infectious Diseases Research	93.855	227,136	-			227,136	-
Allergy and Infectious Diseases Research	93.855	460,261	-			460,261	-
Allergy and Infectious Diseases Research	93.855	667,795	-			667,795	296,766
Allergy and Infectious Diseases Research	93.855	58,571	-			58,571	-
Allergy and Infectious Diseases Research	93.855	237,636	-			237,636	-
Allergy and Infectious Diseases Research	93.855	73,020	-			73,020	-
Allergy and Infectious Diseases Research	93.855	162,634	-			162,634	-
Allergy and Infectious Diseases Research	93.855	488,575	-			488,575	97,098
Allergy and Infectious Diseases Research	93.855	189,588	-			189,588	-
Allergy and Infectious Diseases Research	93.855	269,526	-			269,526	38,444
Allergy and Infectious Diseases Research	93.855	21,914	-			21,914	-
Allergy and Infectious Diseases Research	93.855	5,279	-			5,279	-
Allergy and Infectious Diseases Research	93.855	(1,280)	-			(1,280)	-
Allergy and Infectious Diseases Research	93.855	15,938	-			15,938	-
Allergy and Infectious Diseases Research	93.855	157,237	-			157,237	-
Allergy and Infectious Diseases Research	93.855	-	133,357	Duke University	5R01AI161296-02	133,357	-
Allergy and Infectious Diseases Research	93.855	-	97,666	The Reg of the Univ. of CA, SF Campus	R01AI66967	97,666	-
Allergy and Infectious Diseases Research	93.855	-	241,732	The Reg of the Univ. of CA, SF Campus	R01AI169460	241,732	-
Allergy and Infectious Diseases Research	93.855	-	41,435	New York Blood Center, Inc.	R01AI078314	41,435	-
Allergy and Infectious Diseases Research	93.855	-	19,057	University Of North Carolina At Chapel	R01AI137525	19,057	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Allergy and Infectious Diseases Research	93.855	-	173,787	University Of Alabama at Birmingham	R01AI137338	173,787	-
Allergy and Infectious Diseases Research	93.855	-	129,010	The Trustees of The University of PA	R01AI146101	129,010	-
Allergy and Infectious Diseases Research	93.855	-	(86)	Eastern Virginia Medical School-Conrad	R61AI142685	(86)	-
Allergy and Infectious Diseases Research	93.855	-	19,596	Eastern Virginia Medical School-Conrad	R33AI142685	19,596	-
Allergy and Infectious Diseases Research	93.855	-	148,642	The Rockefeller University	R01AI143810	148,642	-
Allergy and Infectious Diseases Research	93.855	-	320,744	University Of Maryland	R01AI154542	320,744	-
Biomedical Research and Research Training	93.859	126,889	-			126,889	-
Biomedical Research and Research Training	93.859	223,798	-			223,798	-
Biomedical Research and Research Training	93.859	21,241	-			21,241	-
Biomedical Research and Research Training	93.859	417,351	-			417,351	-
Biomedical Research and Research Training	93.859	261,246	-			261,246	-
Biomedical Research and Research Training	93.859	185,923	-			185,923	-
Biomedical Research and Research Training	93.859	123,303	-			123,303	-
Biomedical Research and Research Training	93.859	(30,563)	-			(30,563)	-
Biomedical Research and Research Training	93.859	225,030	-			225,030	-
Biomedical Research and Research Training	93.859	522,467	-			522,467	-
Biomedical Research and Research Training	93.859	357,069	-			357,069	28,696
Biomedical Research and Research Training	93.859	388,723	-			388,723	-
Biomedical Research and Research Training	93.859	213,326	-			213,326	-
Biomedical Research and Research Training	93.859	59,910	-			59,910	-
Biomedical Research and Research Training	93.859	407,063	-			407,063	-
Biomedical Research and Research Training	93.859	346,699	-			346,699	-
Biomedical Research and Research Training	93.859	640,247	-			640,247	167,640
Biomedical Research and Research Training	93.859	301,151	-			301,151	76,399
Biomedical Research and Research Training	93.859	268,987	-			268,987	-
Biomedical Research and Research Training	93.859	585,589	-			585,589	-
Biomedical Research and Research Training	93.859	61,413	-			61,413	-
Biomedical Research and Research Training	93.859	180,657	-			180,657	-
Biomedical Research and Research Training	93.859	35,107	-			35,107	-
Biomedical Research and Research Training	93.859	(12,552)	-			(12,552)	(12,552)
Biomedical Research and Research Training	93.859	(135)	-			(135)	12,552
Biomedical Research and Research Training	93.859	217,117	-			217,117	212,996
Biomedical Research and Research Training	93.859	669,179	-			669,179	294,394
Biomedical Research and Research Training	93.859	45,788	-			45,788	45,788
Biomedical Research and Research Training	93.859	346,880	-			346,880	-
Biomedical Research and Research Training	93.859	-	7,614	SINTX Technologies Corporation	R41GM146268	7,614	-
Biomedical Research and Research Training	93.859	-	63,826	University of Pittsburgh	R35GM142982	63,826	-
Biomedical Research and Research Training	93.859	-	70,049	Columbia University	R01GM137608	70,049	-
Child Health and Human Development Extramural Research	93.865	757,231	-			757,231	616,081
Child Health and Human Development Extramural Research	93.865	(648)	-			(648)	-
Child Health and Human Development Extramural Research	93.865	120,404	-			120,404	-
Child Health and Human Development Extramural Research	93.865	10,869	-			10,869	-
Child Health and Human Development Extramural Research	93.865	175,299	-			175,299	44,368
Child Health and Human Development Extramural Research	93.865	71,543	-			71,543	-
Child Health and Human Development Extramural Research	93.865	137,567	-			137,567	-
Child Health and Human Development Extramural Research	93.865	2,177	-			2,177	-
Child Health and Human Development Extramural Research	93.865	12,855	-			12,855	-
Child Health and Human Development Extramural Research	93.865	284,197	-			284,197	3,557
Child Health and Human Development Extramural Research	93.865	-	20,364	University of Pittsburgh	1R03HD101146-01A1	20,364	-
Child Health and Human Development Extramural Research	93.865	-	572,430	University of Pittsburgh	1R01HD104158-01A1	572,430	409,084
Child Health and Human Development Extramural Research	93.865	60,519	-			60,519	-
Child Health and Human Development Extramural Research	93.865	138,459	-			138,459	-
Child Health and Human Development Extramural Research	93.865	-	20,513	Virginia Polytechnic Institute	P2CHD101912	20,513	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Child Health and Human Development Extramural Research	93.865	-	(6,256)	Temple University	R01HD103904	(6,256)	-
Child Health and Human Development Extramural Research	93.865	-	9,065	Temple University	R01HD103904	9,065	-
Child Health and Human Development Extramural Research	93.865	-	13,960	Indiana University Health, Inc.	9549-TJU	13,960	-
Child Health and Human Development Extramural Research	93.865	-	15,566	RTI International	UG1HD107628	15,566	-
Child Health and Human Development Extramural Research	93.865	-	12,493	Medical University Of South Carolina	P2CHD086844	12,493	-
Child Health and Human Development Extramural Research	93.865	-	7,834	RTI International	624HD107621	7,834	-
Child Health and Human Development Extramural Research	93.865	-	10,564	Nemours Foundation	R01HD102967	10,564	-
Child Health and Human Development Extramural Research	93.865	-	2,290	Temple University	R03HD101064	2,290	-
Child Health and Human Development Extramural Research	93.865	-	43,602	University of Pittsburgh	AWD00000279(132614-1)	43,602	-
Child Health and Human Development Extramural Research	93.865	-	2,577	University of South Carolina	A002240S011	2,577	-
Child Health and Human Development Extramural Research	93.865	-	16,594	Temple University	R01HD103904	16,594	-
Aging Research	93.866	625,134	-			625,134	383,091
Aging Research	93.866	289,707	-			289,707	-
Aging Research	93.866	1,251	-			1,251	-
Aging Research	93.866	255,718	-			255,718	-
Aging Research	93.866	1,162,722	-			1,162,722	-
Aging Research	93.866	273,105	-			273,105	18,916
Aging Research	93.866	289,067	-			289,067	39,792
Aging Research	93.866	6,929	-			6,929	-
Aging Research	93.866	82,251	-			82,251	-
Aging Research	93.866	52,419	-			52,419	-
Aging Research	93.866	7,744	-			7,744	-
Aging Research	93.866	86,996	-			86,996	-
Aging Research	93.866	-	21,780	Temple University	R01AG062503	21,780	-
Aging Research	93.866	-	210,235	George Washington University	U19AG078558	210,235	-
Aging Research	93.866	-	96,948	Wake Forest University	R01AG078153	96,948	-
Aging Research	93.866	-	(6,854)	Wake Forest University	R01AG045551	(6,854)	-
Aging Research	93.866	-	3,759	The Trustees of The University of PA	R01AG061945	3,759	-
Aging Research	93.866	-	2,873	Hennepin Healthcare Research Institute	15156-03-01FFS	2,873	-
Vision Research	93.867	302,301	-			302,301	71,615
Vision Research	93.867	61,154	-			61,154	-
Vision Research	93.867	471,291	-			471,291	158,280
Vision Research	93.867	41,172	-			41,172	-
Vision Research	93.867	(1,235)	-			(1,235)	-
Vision Research	93.867	276,646	-			276,646	-
Vision Research	93.867	-	218,809	The Trustees of The University of PA	R01EY026525	218,809	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	36,741	-			36,741	25,000
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	42	-			42	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	686,316	-			686,316	583,113
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	37,844	-			37,844	20,336
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	294,778	-			294,778	271,795
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	110,022	-			110,022	76,137
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	183,991	-			183,991	182,900
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	8,126	-			8,126	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	380,285	-			380,285	374,068
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	8,604	-			8,604	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	182,208	-			182,208	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	372,385	-			372,385	-
Advanced Development of Multivalent Vaccine Candidate for Filovirus and Lassa Fever	93.RD	2,678	-			2,678	-
Clinical Proteomic Tumor Analysis Consortium	93.RD	-	3,814	Leidos, Corp.	HHSN261200800001E	3,814	-
Total National Institutes of Health		80,051,330	8,479,572			88,530,901	10,332,444

The accompanying notes are an integral part of this schedule

Thomas Jefferson University

Schedule of Expenditures of Federal Awards

June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Food and Drug Administration							
Food and Drug Administration Research	93.103	-	22,301	Emory University	R01FD005746	22,301	-
Total Food and Drug Administration		-	<u>22,301</u>			<u>22,301</u>	-
Centers for Disease Control							
Special Programs for the Aging, Title IV, and Title II, Discretionary Projects	93.048	-	6,603	National Council on Aging	90HDC0008	6,603	-
Disabilities Prevention	93.184	-	3,667	The Children's Hospital of Philadelphia	NU27DD000020	3,667	-
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	93.185	-	1,285	CDC Foundation	NH23IP922652	1,285	-
National Research Service Award in Primary Care Medicine	93.186	178,836	-			178,836	19,045
National Research Service Award in Primary Care Medicine	93.186	260,052	-			260,052	-
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	-	88,838	City Of Philadelphia - DOPH	CK 19 1904	88,838	-
Total Centers for Disease Control		<u>438,888</u>	<u>100,394</u>			<u>539,282</u>	<u>19,045</u>
Administration for Community Living							
Paralysis Resource Center	93.325	-	72,397	PAI Life Sciences, Inc	90PRRC0004	72,397	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	27,405	-			27,405	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	169,024	-			169,024	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	12,623	University Of Alabama at Birmingham	90SIMS0016-01-00	12,623	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	14,123	University Of Alabama at Birmingham	90ISM0016-02-00	14,123	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	4,819	Temple University	90IFDV0018-01-00	4,819	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	223,501	-			223,501	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	20,108	-			20,108	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	137,373	Shepherd Center, Inc.	SHEP-19-0016	137,373	-
ACL National Institute on Disability, Independent Living, and Rehabilitation Research	93.433	-	14,962	Indiana University	8692	14,962	-
Developmental Disabilities Basic Support and Advocacy Grants	93.630	-	42,929	Pennsy Development Disabilities Council	4100092146	42,929	-
Total Administration for Community Living		<u>440,038</u>	<u>299,226</u>			<u>739,265</u>	-
Agency for Healthcare Research and Quality Healthcare Research							
Research on Healthcare Costs, Quality and Outcomes	93.226	222,645	-			222,645	45,151
Research on Healthcare Costs, Quality and Outcomes	93.226	21,850	-			21,850	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-	4,685	Nemours Foundation	R18HS027399	4,685	-
Research on Healthcare Costs, Quality and Outcomes	93.226	-	154,431	Nemours Foundation	R18HS027399	154,431	-
Total Agency for Healthcare Research and Quality Healthcare Research		<u>244,495</u>	<u>159,116</u>			<u>403,611</u>	<u>45,151</u>
Health Resources and Services Administration							
Maternal and Child Health Federal Consolidated Programs	93.110	-	(1,401)	The Children's Hospital Of Philadelphia	H30MC24050	(1,401)	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	4,594	The Children's Hospital Of Philadelphia	2H30MC24050-11-00	4,594	-
Maternal and Child Health Federal Consolidated Programs	93.110	-	12,299	Lehigh Valley Hlth Netw & Compo Entities	7H30MC48960-01-00	12,299	-
Injury Prevention and Control Research and State and Community Based Programs	93.136	123,316	-			123,316	-
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153	-	35,528	Mazzoni Center	H12HA24852	35,528	-
Geriatric Academic Career Awards	93.250	80,889	-			80,889	-
Capacity Building Assistance to Strengthen Public Health Immunization Infrastructure and Performance financed in part by the Prevention and Public Health Fund (PPHF)	93.732	408,114	-			408,114	-
Capacity Building Assistance to Strengthen Public Health Immunization Infrastructure and Performance financed in part by the Prevention and Public Health Fund (PPHF)	93.732	394,133	-			394,133	-
Grants for Primary Care Training and Enhancement	93.884	51,342	-			51,342	-
Total Health Resources and Services Administration		<u>1,057,794</u>	<u>51,021</u>			<u>1,108,814</u>	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University

Schedule of Expenditures of Federal Awards

June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Assistant Secretary for Preparedness and Response							
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities	93.817			Commonwealth of Pennsylvania	SAP 4100070353	-	-
Total Assistant Secretary for Preparedness and Response		-	-			-	-
Centers for Medicare and Medicaid Services							
Accountable Health Communities	93.650	-	-	Camden Coalition of Healthcare Providers	P1CMS331574	-	-
Total Centers for Medicare and Medicaid Services		-	-			-	-
Total Department of Health and Human Services		82,232,544	9,111,629			91,344,174	10,396,640
DEPARTMENT OF DEFENSE							
Basic and Applied Scientific Research	12.300	(6,392)	-			(6,392)	-
Naval Medical Research and Development	12.340	39,121	-			39,121	-
Military Medical Research and Development	12.420	49,606	-			49,606	23,937
Military Medical Research and Development	12.420	102,530	-			102,530	-
Military Medical Research and Development	12.420	43,470	-			43,470	-
Military Medical Research and Development	12.420	45,150	-			45,150	-
Military Medical Research and Development	12.420	178,083	-			178,083	-
Military Medical Research and Development	12.420	(405)	-			(405)	-
Military Medical Research and Development	12.420	131,113	-			131,113	-
Military Medical Research and Development	12.420	163,511	-			163,511	-
Military Medical Research and Development	12.420	107,469	-			107,469	-
Military Medical Research and Development	12.420	132,047	-			132,047	35,132
Military Medical Research and Development	12.420	184,308	-			184,308	-
Military Medical Research and Development	12.420	102,612	-			102,612	75,412
Military Medical Research and Development	12.420	214,391	-			214,391	2,655
Military Medical Research and Development	12.420	142,297	-			142,297	38,791
Military Medical Research and Development	12.420	139,773	-			139,773	-
Military Medical Research and Development	12.420	78,313	-			78,313	-
Military Medical Research and Development	12.420	139,482	-			139,482	26,502
Military Medical Research and Development	12.420	72,064	-			72,064	-
Military Medical Research and Development	12.420	56,702	-			56,702	-
Military Medical Research and Development	12.420	46,125	-			46,125	-
Military Medical Research and Development	12.420	83,971	-			83,971	-
Military Medical Research and Development	12.420	233,163	-			233,163	-
Military Medical Research and Development	12.420	175,421	-			175,421	55,460
Military Medical Research and Development	12.420	278,407	-			278,407	-
Military Medical Research and Development	12.420	64,978	-			64,978	-
Military Medical Research and Development	12.420	1,226,590	-			1,226,590	-
Military Medical Research and Development	12.420	241,765	-			241,765	-
Military Medical Research and Development	12.420	105,136	-			105,136	3,629
Military Medical Research and Development	12.420	9,262	-			9,262	-
Military Medical Research and Development	12.420	120,536	-			120,536	-
Military Medical Research and Development	12.420	75,382	-			75,382	-
Military Medical Research and Development	12.420	10,080	-			10,080	-
Military Medical Research and Development	12.420	20,966	-			20,966	-
Military Medical Research and Development	12.420	-	3,064	University Of Maryland	W81XWH2010432	3,064	-
Military Medical Research and Development	12.420	-	45,454	University Of Maryland	W81XWH2010432	45,454	-
Military Medical Research and Development	12.420	-	7,065	Temple University	W81XWH2110637	7,065	-
Military Medical Research and Development	12.420	-	19,484	University Of Oklahoma Health Sciences C	W81XWH2110003	19,484	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Military Medical Research and Development	12.420	-	29,159	Drexel University	W81XWH2110524	29,159	-
Military Medical Research and Development	12.420	-	42,034	University Of Minnesota	W81XWH2110589	42,034	-
Military Medical Research and Development	12.420	-	29,714	Yale University	W81XWH2010310	29,714	-
Military Medical Research and Development	12.420	-	74,611	Yale University	W81XWH2110142	74,611	-
Military Medical Research and Development	12.420	-	34,900	Drexel University	W81XWH2010349	34,900	-
Military Medical Research and Development	12.420	-	13,749	University of Miami	W81XWH-16-1-0756	13,749	-
Military Medical Research and Development	12.420	-	2,761	University Of Oklahoma Health Sciences C	W81XWH19103576	2,761	-
Military Medical Research and Development	12.420	-	28,618	Columbia University	W81XWH2010887	28,618	-
Military Medical Research and Development	12.420	-	25,213	H. Lee Moffitt CA Cent and Res. Inst.	W81XWH2010351	25,213	-
Military Medical Research and Development	12.420	-	30,630	University Of Oklahoma Health Sciences C	W81XWH2010554	30,630	-
Total Department of Defense		<u>4,807,026</u>	<u>386,457</u>			<u>5,193,483</u>	<u>261,519</u>
DEPARTMENT OF ENERGY							
Conservation Research and Development	81.086	118,873	-			118,873	10,125
Total Department of Energy		<u>118,873</u>	<u>-</u>			<u>118,873</u>	<u>10,125</u>
DEPARTMENT OF AGRICULTURE							
Agriculture and Food Research Initiative (AFRI)	10.310	14,935	-			14,935	-
Total Department of Agriculture		<u>14,935</u>	<u>-</u>			<u>14,935</u>	<u>-</u>
DEPARTMENT OF TRANSPORTATION							
Highway Research and Development Program	20.200			Virginia Polytechnic Institute	418503-19406	-	-
Total Department of Transportation		<u>-</u>	<u>-</u>			<u>-</u>	<u>-</u>
National Science Foundation							
Mathematical and Physical Sciences- RD - National Science Foundation - own cluster	47.049	-	15,253	Rensselaer Polytechnic Institute	2037357	15,253	-
Total National Science Foundation		<u>-</u>	<u>15,253</u>			<u>15,253</u>	<u>-</u>
National Endowment for the Humanities							
Promotion of the Humanities Teaching and Learning Resources and Curriculum Development	45.162	-	(154)	Teagle Foundation	AH-274009-20	(154)	-
Promotion of the Humanities Teaching and Learning Resources and Curriculum Development	45.162	-	41,450	Teagle Foundation	AH274009	41,450	-
Total National Endowment for the Humanities		<u>-</u>	<u>41,297</u>			<u>41,297</u>	<u>-</u>
EXECUTIVE OFFICE OF THE PRESIDENT							
Research and Data Analysis	95.007	19,806	-			19,806	-
Total Executive Office of the President		<u>19,806</u>	<u>-</u>			<u>19,806</u>	<u>-</u>
TOTAL RESEARCH AND DEVELOPMENT CLUSTER		<u>\$ 87,193,184</u>	<u>\$ 9,554,635</u>			<u>\$ 96,747,819</u>	<u>\$ 10,668,283</u>

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
WIOA Cluster							
DEPARTMENT OF LABOR							
WIOA Dislocated Worker National Reserve Demonstration Grants	17.280	-	16	Philadelphia Works Inc.	PW19-066	16	-
Total Department of Labor		-	16			16	-
TOTAL WIOA CLUSTER		-	16			16	-
SNAP Cluster							
DEPARTMENT OF AGRICULTURE							
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	-	955,873	The Pennsylvania State University	S002381-COP-FUN	955,873	-
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	-	1,726,896	The Pennsylvania State University	S002381-COP-FUN	1,726,896	-
Total Department of Agriculture		-	2,682,769			2,682,769	-
TOTAL SNAP CLUSTER		-	2,682,769			2,682,769	-
Economic Development Cluster							
DEPARTMENT OF COMMERCE							
Economic Adjustment Assistance	11.307	-	47,221	Southern Regional Education Board	01-69-15092	47,221	-
Total Department of Commerce		-	47,221			47,221	-
TOTAL ECONOMIC DEVELOPMENT CLUSTER		-	47,221			47,221	-
Other Sponsored Programs							
DEPARTMENT OF THE INTERIOR							
Adaptive Science	15.670	-	21,113	National Audubon Society	N/A	21,113	-
Total Department of the Interior		-	21,113			21,113	-
AGENCY FOR INTERNATIONAL DEVELOPMENT							
USAID Foreign Assistance for Programs Overseas	98.001	-	-	Eastern Virginia Medical School-Conrad	N/A	-	-
Total Agency of International Development		-	-			-	-
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION							
Exploration	43.003	46,216	-			46,216	-
Total National Aeronautics and Space Administration		46,216	-			46,216	-
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
Substance Abuse and Mental Health Services Administration							
Community Programs to Improve Minority Health Grant Program	93.137	137,966	-			137,966	-
Total Assistance Listing 93.137		137,966	-			137,966	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University

Schedule of Expenditures of Federal Awards

June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	120,829	-			120,829	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	50,994	-			50,994	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	90,952	-			90,952	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	153,339	-			153,339	80,254
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	448,325	-			448,325	30,585
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	12,873	PA DHS-OMHSAS	4000025628	12,873	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	169,736	Penn Dept. of Health and Human Services	H79SM086062	169,736	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	1,408	Commonwealth Of Pennsylvania	SM58386	1,408	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	176,453	Department of Human Services	H79SM082107	176,453	-
Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	-	144,022	Penn Dept. of Health and Human Services	H79SM083371	144,022	-
Total Assistance Listing 93.243		<u>864,439</u>	<u>504,493</u>			<u>1,368,931</u>	<u>110,839</u>
Opioid STR	93.788	(1)	-			(1)	-
Opioid STR	93.788	10,931	-			10,931	-
Opioid STR	93.788	69,110	-			69,110	-
Total Assistance Listing 93.788		<u>80,040</u>	<u>-</u>			<u>80,040</u>	<u>-</u>
Block Grants for Community Mental Health Services	93.958	-	7,978	Philadelphia Department of Behavioral Health and Intellectual Disability Services	21-20250-01	7,978	-
Block Grants for Community Mental Health Services	93.958	271,502	-			271,502	-
Total Assistance Listing 93.958		<u>271,502</u>	<u>7,978</u>			<u>279,480</u>	<u>-</u>
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	7,156	Philadelphia Department of Behavioral Health and Intellectual Disability Services	21-20250-01	7,156	-
Total Assistance Listing 93.959		<u>-</u>	<u>7,156</u>			<u>7,156</u>	<u>-</u>
Total Substance Abuse and Mental Health Services Administration		<u>1,353,946</u>	<u>519,626</u>			<u>1,873,572</u>	<u>110,839</u>
Centers for Disease Control and Prevention							
Blood Disorder Program: Prevention, Surveillance, and Research	93.080	-	3,136	Lehigh Valley Hlth Netw & Compo Entities	5NU27DD000020-03-00	3,136	-
Total Assistance Listing 93.080		<u>-</u>	<u>3,136</u>			<u>3,136</u>	<u>-</u>
Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases	93.083	-	82,162	Am Soc of Clinical Onc Cncr Found (ASCO)	1 NH23IP922656-01-00	82,162	-
Total Assistance Listing 93.083		<u>-</u>	<u>82,162</u>			<u>82,162</u>	<u>-</u>
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	-	7,042	Colorado Department Of Public Health	NU50CK000475	7,042	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	-	13,332	Colorado Department Of Public Health	NU50CK000475	13,332	-
Total Assistance Listing 93.283		<u>-</u>	<u>20,373</u>			<u>20,373</u>	<u>-</u>
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	93.323	-	2,434,417	NJ Department Of Health And Senior Servi	NU50CK000525	2,434,417	-
Total Assistance Listing 93.323		<u>-</u>	<u>2,434,417</u>			<u>2,434,417</u>	<u>-</u>
Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises	93.391	-	169,627	The Pennsylvania State University	SAP # 41000090128	169,627	-
Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises	93.391	-	42,708	Pennsylvania Department Of Health	4100091384	42,708	-
Total Assistance Listing 93.391		<u>-</u>	<u>212,335</u>			<u>212,335</u>	<u>-</u>

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke-Financed in part by 2018 Prevention and Public Health Funds	93.435	-	41,972	City Of Philadelphia - DOPH	NU380T000286	41,972	-
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke-Financed in part by 2018 Prevention and Public Health Funds	93.435	-	64,285	City Of Philadelphia - DOPH	1920560-03	64,285	-
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke-Financed in part by 2018 Prevention and Public Health Funds	93.435	-	108,447	City Of Philadelphia - DOPH	1920560-03	108,447	-
Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke-Financed in part by 2018 Prevention and Public Health Funds	93.435	-	7,007	City Of Philadelphia - DOPH	1920560-03	7,007	-
Total Assistance Listing 93.435		-	<u>221,711</u>			<u>221,711</u>	-
Emerging Infections Sentinel Networks	93.860	-	171,660	University Of California, Los Angeles	U01CK000643	171,660	-
Total Assistance Listing 93.860		-	<u>171,660</u>			<u>171,660</u>	-
Total Centers for Disease Control and Prevention		-	<u>3,145,794</u>			<u>3,145,794</u>	-
Health Resources and Services Administration							
HIV-Related Training and Technical Assistance	93.145	-	274,520	Columbia University	U10HA29291	274,520	-
HIV-Related Training and Technical Assistance	93.145	-	47,722	Columbia University	U10HA29291	47,722	10,000
Total Assistance Listing 93.145		-	<u>322,242</u>			<u>322,242</u>	<u>10,000</u>
Nurse Anesthetist Traineeship	93.124	39,369	-			39,369	-
Total Assistance Listing 93.124		<u>39,369</u>	-			<u>39,369</u>	-
Ending the HIV Epidemic: A Plan for America	93.686	-	88,785	City of Philadelphia	EH1006	88,785	-
Ending the HIV Epidemic: A Plan for America	93.686	-	28,336	City of Philadelphia	EH1006	28,336	-
Ending the HIV Epidemic: A Plan for America	93.686	-	102,111	City of Philadelphia	21-20663	102,111	-
Ending the HIV Epidemic: A Plan for America	93.686	-	47,705	City of Philadelphia	21-20663	47,705	-
Ending the HIV Epidemic: A Plan for America	93.686	-	6,615	City of Philadelphia	N/A	6,615	-
Total Assistance Listing 93.686		-	<u>273,552</u>			<u>273,552</u>	-
Grants for Primary Care Training and Enhancement	93.884	409,696	-			409,696	-
Grants for Primary Care Training and Enhancement	93.884	438,394	-			438,394	2,700
Total Assistance Listing 93.884		<u>848,091</u>	-			<u>848,091</u>	<u>2,700</u>
HIV Emergency Relief Project Grants	93.914	-	106,288	City of Philadelphia	RS2654	106,288	-
HIV Emergency Relief Project Grants	93.914	-	36,397	City of Philadelphia	RS2654	36,397	-
HIV Emergency Relief Project Grants	93.914	-	41,428	City of Philadelphia	RS2874	41,428	-
HIV Emergency Relief Project Grants	93.914	-	7,367	City of Philadelphia	RS2874	7,367	-
HIV Emergency Relief Project Grants	93.914	-	31,993	City of Philadelphia	RW2417	31,993	-
HIV Emergency Relief Project Grants	93.914	-	11,796	City of Philadelphia	RW2417	11,796	-
HIV Emergency Relief Project Grants	93.914	-	204,927	City of Philadelphia	RW2925	204,927	-
HIV Emergency Relief Project Grants	93.914	-	87,358	City of Philadelphia	RW2925	87,358	-
HIV Emergency Relief Project Grants	93.914	-	42,108	City of Philadelphia	RS2583	42,108	-
HIV Emergency Relief Project Grants	93.914	-	21,362	City of Philadelphia	2120576-01	21,362	-
HIV Emergency Relief Project Grants	93.914	-	112,804	City of Philadelphia	RW1336	112,804	-
HIV Emergency Relief Project Grants	93.914	-	49,756	City of Philadelphia	RW1399	49,756	-
HIV Emergency Relief Project Grants	93.914	-	27,372	City of Philadelphia	RW1399	27,372	-
HIV Emergency Relief Project Grants	93.914	-	39,453	City of Philadelphia	RW1399	39,453	-
HIV Emergency Relief Project Grants	93.914	-	345,337	City of Philadelphia	RW1582	345,337	-
HIV Emergency Relief Project Grants	93.914	-	157,724	City of Philadelphia	RW2582	157,724	-
HIV Emergency Relief Project Grants	93.914	-	130,814	City of Philadelphia	RW1584	130,814	-

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
HIV Emergency Relief Project Grants	93.914	-	51,198	City of Philadelphia	RW2584	51,198	-
Total Assistance Listing 93.914		-	1,505,482			1,505,482	-
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	297,130	-			297,130	-
Total Assistance Listing 93.918		297,130	-			297,130	-
Healthy Start Initiative	93.926	801,209	-			801,209	-
Total Assistance Listing 93.926		801,209	-			801,209	-
HIV Prevention Activities Health Department Based	93.940	-	208,197	City of Philadelphia	CP2049	208,197	-
HIV Prevention Activities Health Department Based	93.940	-	200,199	City of Philadelphia	CP2049	200,199	-
Total Assistance Listing 93.940		-	408,396			408,396	-
Maternal and Child Health Services Block Grant to the States	93.994	-	60,571	Commonwealth of Pennsylvania	4100088247	60,571	-
Total Assistance Listing 93.994		-	60,571			60,571	-
Total Health Resources and Services Administration		1,985,798	2,570,244			4,556,042	12,700
Substance Abuse and Mental Health Services Administration							
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	281,300	City of Philadelphia	21-20038-04	281,300	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	6,266	City of Philadelphia	21-20038	6,266	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	410,548	City of Philadelphia	21-20037	410,548	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	91,106	City of Philadelphia	21-20037	91,106	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	75,713	-			75,713	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	38,950	PA Dept. of Drug and Alcohol Programs	1Bo8TI083542	38,950	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	401,918	PA Dept. of Drug and Alcohol Programs	1Bo8TI083542	401,918	-
Block Grants for Prevention and Treatment of Substance Abuse	93.959	-	2,207	PA Dept. of Drug and Alcohol Programs	1Bo8T1083542	2,207	-
Total Assistance Listing 93.959		75,713	1,232,294			1,308,007	-
Total Substance Abuse and Mental Health Services Administration		75,713	1,232,294			1,308,007	-
Office of Population Affairs							
Family Planning Services	93.217	-	(8,078)	AccessMatters	100-401	(8,078)	-
Family Planning Services	93.217	-	23,219	AccessMatters	100-401	23,219	-
Family Planning Services	93.217	-	5,168	AccessMatters	100-401	5,168	-
Total Assistance Listing 93.217		-	20,309			20,309	-
Total Office of Population Services		-	20,309			20,309	-
Centers for Medicare and Medicaid Services							
Children's Health Insurance Program	93.767	-	13,352,902	Pennsylvania Insurance Department	INSCHIP 2008-4	13,352,902	-
Total Assistance Listing 93.767		-	13,352,902			13,352,902	-
Total Centers for Medicare and Medicaid Services		-	13,352,902			13,352,902	-
Total Department of Health and Human Services		\$ 3,415,456.96	\$ 20,841,169.43			\$ 24,256,626.39	\$ 123,539.28

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Schedule of Expenditures of Federal Awards
June 30, 2023

Federal Program	Assistance Listing #	Direct	Pass-Through	Pass-through Entity	Pass-Through Entity Sponsor Number	Total Expenditures	Passed to Subrecipients
COVID-19 Programs							
Covid -19 - Coronavirus Relief Fund	21.019	-	4,077	Penn Dept. of Health and Human Services	4100086662	4,077	-
Covid -19 - Coronavirus Relief Fund	21.019	-	(3,925)	Penn Dept. of Health and Human Services	4100086662	(3,925)	-
Covid -19 - Coronavirus Relief Fund	21.019	-	109,395	Penn Dept. of Health and Human Services	4100086662	109,395	75,000
Total Assistance Listing 21.019		-	109,547			109,547	75,000
American Rescue Plan Act	21.027	-	15,914,096	Penn Dept. of Health and Human Services	4100086662	15,914,096	-
Total Assistance Listing 21.027		-	15,914,096			15,914,096	-
Covid-19- Immunization Cooperative Agreements	93.268	-	472,621	New Jersey Department of Health	NH23IP922594	472,621	-
Covid-19- Immunization Cooperative Agreements	93.268	-	37,380	PMHCC	NH23IP922583/NU50CK00052	37,380	-
Covid-19- Immunization Cooperative Agreements	93.268	-	60,857	PMHCC	NH23IP922583/NU50CK00052	60,857	-
Total Assistance Listing 93.268		-	570,858			570,858	-
COVID 19- Emergency Grants to Address Mental and Substance Use Disorders During COVID-19	93.665	-	26,207	Center for Community Resources	H79FG000486	26,207	-
Total Assistance Listing 93.665		-	26,207			26,207	-
Covid-19 Provider Relief Funds							
COVID-19 - General Distribution - Phase 3 Reconsideration	93.498	58,362,389	-			58,362,389	-
COVID-19 - General Distribution - Phase 4	93.498	51,124,942	-			51,124,942	-
COVID-19 - ARP Rural	93.498	1,096,520	-			1,096,520	-
COVID-19 - JV - PRF	93.498	532,931	-			532,931	-
Total Assistance Listing 93.498		111,116,782	-			111,116,782	-
FEMA Reimbursement Program through NJ	97.036	-	7,857,563	NJ	N/A	7,857,563	-
FEMA Reimbursement Program through PA	97.036	-	2,563,425	PEMA	N/A	2,563,425	-
Total Assistance Listing 97.036		-	10,420,989			10,420,989	-
Total COVID-19 Programs			\$ 27,041,696			\$ 138,158,479	\$ 75,000
TOTAL OTHER SPONSORED PROGRAMS			\$ 47,903,979			\$ 162,482,434	\$ 198,539
TOTAL FEDERAL AWARD EXPENDITURES			\$ 60,188,621			\$ 400,730,524	\$ 10,866,822

The accompanying notes are an integral part of this schedule

Thomas Jefferson University

Notes to Schedule of Expenditures of Federal Awards

June 30, 2023

1. Reporting Entity

Thomas Jefferson University (“Jefferson” or the “University”) is an independent, non-profit corporation organized under the laws of the Commonwealth of Pennsylvania and recognized as a tax-exempt organization pursuant to Section 501(c)(3) of the Internal Revenue Code. The University has a tripartite mission of education, research, and patient care.

The University conducts research and offers undergraduate and graduate instruction through the Sidney Kimmel Medical College, the Jefferson College of Nursing, the Jefferson College of Pharmacy, the Jefferson College of Health Professions, the Jefferson College of Population Health, the Jefferson College of Biomedical Sciences, and the Kanbar College of Design, Engineering and Commerce, the School of Continuing and Professional Studies, the College of Architecture and the Built Environment, and the College of Science, Health, and Liberal Arts. The combined institution has approximately 7,370 students and is located in Philadelphia, Pennsylvania, with additional campus locations in the Greater Philadelphia Region and Atlantic City, New Jersey.

For the year ended June 30, 2023, the integrated healthcare organization included TJUH System (“TJUHS”), Abington Health (“Abington”), Jefferson Health Northeast System (“JHNES”), Kennedy Health System (“Kennedy”), Magee Rehabilitation Hospital (“Magee”), and Albert Einstein Health Network (“AEHN”). The integrated healthcare organization provides inpatient, outpatient, and emergency care services through acute care, ambulatory care, rehabilitation care, physician and other primary care services for residents of the Greater Philadelphia Region.

Additionally, the integrated healthcare organization includes Health Partners Plans (HPP). HPP provides access to healthcare services on a prepaid basis. HPP is licensed by the Commonwealth Departments of Insurance and Health to operate as a Health Maintenance Organization.

Federal Identification Numbers for reporting entities included in this report are 23-1352651 for the University, 23- 2829095 for Thomas Jefferson University Hospital, 23-1352152 for Abington Memorial Hospital, 23-0596940 for Jefferson Health - Northeast, 22-1773439 for Kennedy University Hospital, Inc., 23-1396794 for Albert Einstein Medical Center, 26-3359979 for Lansdale Hospital Corporation, 23-1476328 for Magee Rehabilitation Hospital, 23-2691968 for Aria Health Physician Services, 46-0779942 for Aria Health Orthopedics, 47-2639286 for Jefferson Acute Care Physicians, P.C., 23-2809585 for Jefferson University Physicians, 23-2678055 for Methodist Associates in Healthcare, Inc., 46-1420853 for Kennedy Medical Group Practice, P.C., 46-4855345 for Jefferson University Physicians of New Jersey, 23-2858320 for Jefferson Medical Care, 22-2442032 for Kennedy Health Facilities, Inc., 23-2622006 for Walnut Home Therapeutics, Inc., 20-4193243 for Einstein Medical Center Montgomery, 23-2275991 for Fornance Physicians Inc., 23-2664784 for Einstein Practice Plan, Inc., 23-2760086 for Einstein Community Health Associates, and 23-2379751 for HPP.

2. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) presents a summary of certain activities of the University for the year ended June 30, 2023. Negative amounts represent current year adjustments of amounts reported in prior years. Assistance listing and pass-through entity numbers are included when available. The information in the schedule is presented in accordance with the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the

Thomas Jefferson University

Notes to Schedule of Expenditures of Federal Awards

June 30, 2023

“Uniform Guidance”). Therefore, some amounts presented in the schedule may differ from amounts presented in, or used in the preparation of, the basic consolidated financial statements of the University.

Amounts presented related to expenditures of HPP programs are inclusive of the 18-month period ending June 30, 2023. The University acquired a controlling interest in HPP on November 1, 2021. Independent auditors’ reports were issued by other auditors to the Board of Directors of HPP for the year ending December 31, 2021 for HPP’s Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statement Performed in Accordance With Government Auditing Standards and Compliance for the Major Federal Program and Report on Internal Control Over Compliance.

For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly by the University with agencies and departments of the federal government and all sub awards to the University by nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

3. Summary of Significant Accounting Policies

Expenditures reported in the Schedule are reported on the accrual basis of accounting. Expenditures include a portion of costs associated with general university activities which are allocated to awards under negotiated formulas commonly referred to as facilities and administrative cost rates.

Expenditures for certain non-student financial aid awards include indirect costs. The University generally applies its predetermined approved facilities and administrative rate when charging indirect costs to federal awards rather than the 10% de minimis cost rate as described in Section 200.414 of the Uniform Guidance.

Expenditures for federal student financial aid programs are recognized as incurred and include Federal Pell program grants to students, the federal share of students’ FSEOG program grants, Federal Work-Study program earnings, loans to students under federally guaranteed programs and certain other federal financial assistance grants for students and administrative cost allowances, where applicable.

Expenditures for other federal awards of the University are determined using the cost accounting principles and procedures set forth in the Uniform Guidance. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement.

4. Student Loan Programs

The Federal student loan programs listed below are administered directly by the University and balances and transactions relating to these programs are included in the University’s consolidated financial statements. Loans outstanding at the beginning of the year, the administrative cost allowance and loans made during the year are included in the federal expenditures presented in the Schedule. The balance of loans outstanding at June 30, 2023 consists of:

Thomas Jefferson University
Notes to Schedule of Expenditures of Federal Awards
June 30, 2023

	Assistance Listing #	Loan Balance
Health Professions Student Loans, Including Primary Care Loans/Loans for Disadvantaged Students	93.342	\$ 997,916
Nursing Student Loans	93.364	2,711,483
Perkins Loan Programs	84.038	1,754,265
Nurse Faculty Loan Program	93.264	190,641

5. Federal Direct Loan Program (FDLP)

During the fiscal year ended June 30, 2023 the University processed new loans to students under the Direct Student Loan Program assistance listing # 84.268, which includes subsidized and unsubsidized Stafford Loans and Supplemental Loans for Students. The University is responsible only for the performance of certain administrative duties with respect to the FDLP and, accordingly, these loans are not included in the University's basic consolidated financial statements. Loans made during the year are included in the federal expenditures presented in the Schedule. It is not practical to determine the balance of loans outstanding under these programs at June 30, 2023.

6. Provider Relief Funds

The Schedule includes grant activity related to the Department of Health and Human Services ("HHS") Coronavirus Aid Relief and Economic Security (CARES) Act Assistance Listing Number 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 4 and 5 funds received between July 1, 2021 and June 30, 2022, and expended by June 30, 2023 as reported to HRSA via the PRF Reporting Portal. The Schedule thus includes \$3.4M of direct expenditures and \$107.7M in lost revenue.

7. Federal Emergency Management Agency ("FEMA")

As of June 30, 2023, the University received approval during 2023 for \$10.4M of claims submitted to FEMA under Assistance Listing Number 97.036. The claims submitted represented incurred expenses attributed to the University's response to COVID-19. The fiscal year 2023 Schedule of Expenditures of Federal Awards includes expenses of \$10.4M which were incurred in a prior year.

II. Reports on Internal Controls and Compliance



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees
Thomas Jefferson University:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Thomas Jefferson University and its subsidiaries (the "University"), which comprise the consolidated balance sheets as of June 30, 2023, and the related consolidated statements of operations and changes in net assets without donor restrictions, of changes in net assets, and of cash flows for the year then ended, including the related notes (collectively referred to as the "consolidated financial statements"), and have issued our report thereon dated October 20, 2023, except with respect to the opinion on the schedule of financial responsibility ratios, as which the date is April 1, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania
October 20, 2023, except with respect to the opinion on the schedule of financial responsibility ratios, as to which the date is April 1, 2024



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over
Compliance in Accordance with the Uniform Guidance**

To the Board of Trustees
Thomas Jefferson University:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Thomas Jefferson University's (the "University") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2023. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually



or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance and which are described in the accompanying schedule of findings and questioned costs as items 2023-001, 2023-002, 2023-003, and 2023-004. Our opinion on each major federal program is not modified with respect to these matters.

Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The University's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over



compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Privatehouse Cooper LLP

Philadelphia, Pennsylvania
April 1, 2024

III. Findings and Questioned Costs

**Thomas Jefferson University
Federal Awards
Schedule of Findings and Questioned Costs
June 30, 2023**

I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued: Unmodified

Internal control over financial reporting:

• Material weakness(es) identified?	_____ yes	<u> X </u> no
• Significant deficiency(ies) identified that are not considered to be material weaknesses?	_____ yes	<u> X </u> none reported
• Non-compliance material to financial statements noted?	_____ yes	<u> X </u> no

Federal Awards

Internal control over major programs:

• Material weakness(es) identified?	_____ yes	<u> X </u> no
• Significant deficiency(ies) identified that are not considered to be material weaknesses?	_____ yes	<u> X </u> none reported

Type of auditor’s report issued on compliance for major programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516 (a)?	<u> X </u> yes	___ no
---	------------------	--------

Identification of major programs assistance listing number(s): 93.498 84.425F R&D Cluster 97.036 21.027	Name of Federal and City Program or Cluster Provider Relief Funds (PRF) COVID-19 Education Stabilization Fund (HEERF) Research and Development Cluster Disaster Grants – Public Assistance (Presidentially Declared Disasters) Coronavirus State & Local Fiscal Recovery Funds	
Dollar threshold used to distinguish between type A and type B programs:	\$3,000,000	
Auditee qualified as low-risk auditee?	_____ yes	<u> X </u> no

Section II – Financial Statement Findings

There are no matters to report.

Thomas Jefferson University
Federal Awards
Schedule of Findings and Questioned Costs
June 30, 2023

Section III – Federal Award Findings and Questioned Costs

Finding 2023-001 Reporting of PRF Expenses

Grantor(s): Health Resources and Services Administration

Program: COVID-19 Provider Relief Fund (PRF)

Assistance Listing#: 93.498

Title: COVID-19 - Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

Award Year: 7/2022 – 6/2023

Award #: N/A

Pass-through Number: N/A

Criteria

As specified in the Provider Relief Fund Distributions and American Rescue Plan Rural Distribution Post-Payment Notice of Reporting Requirements, issued on June 11, 2021 and updated on October 27, 2022 and April 7, 2023, Provider Relief Fund (PRF) recipients who received one or more payments exceeding \$10,000 in the aggregate during a Payment Received Period are required to report in each applicable Reporting Period. Step four requires recipients to report on expenses paid for with payments received (including any interest earned). Expense categories will include general and administrative and/or other health care-related expenses by calendar year quarter.

Condition

The University reported total general and administrative and other health care-related expenses of \$133,333 (for the period January 1, 2021 to June 30, 2021) in the PRF Reporting Portal Submission for Period 3 for the Jefferson University Physicians entity. The University duplicated the reporting of these expenses (for the period July 1, 2021 to December 31, 2021) in the PRF Reporting Portal Submission for Period 4 for the same entity.

Cause

This finding was due to insufficient review of the report before submission.

Effect

The duplicate reporting of expenses in the PRF Portal Submission for Period 3 and Period 4 resulted in an incorrect calculation of the “Total Payments Used for Lost Revenues in the Current Reporting Period” section in the “Lost Revenue Summary” section of the PRF Portal Submission for Period 4. The calculated amount of “Total Payments Used for Lost Revenues in the Current Reporting Period” for Period 4 was calculated as \$3,084,081 whereas the amount would have been \$3,217,414 if the expenses had not been duplicated in the Period 4 PRF Portal Submission Reporting for the Jefferson University Physicians entity.

Questioned Costs

None.

Recommendation

Management should enhance the control in place to review each line item and ensure agreement to underlying support on the PRF portal prior to submission.

Management’s View and Corrective Action Plan

Management’s response is included in “Management’s Views and Corrective Action Plan” included in this Report.

Thomas Jefferson University
Federal Awards
Schedule of Findings and Questioned Costs
June 30, 2023

Finding 2023-002 Equipment Observations R&D

Grantor(s): Various

Program: Research and Development Cluster

Assistance Listing#: Various

Title: Research and Development Cluster

Award Year: 7/2022 – 6/2023

Award #: N/A

Pass-through Number: N/A

Criteria

Non-federal entities other than states must follow 2 CFR sections 200.313(c) through (e) which require that a physical inventory of the property must be taken, and the results reconciled with the property records at least once every two years (2 CFR section 200.313(d)(2)).

Condition

The University performs a physical inventory of equipment at the department level. Within the Research and Development Cluster, there are 18 departments. Of the 18 departments, 5 departments did not perform the physical inventory at least once in the last two-year period (FY23 and FY22). These 5 departments included 25 individual equipment items that totaled \$711,698. The remaining population of 13 departments appropriately performed the physical inventory in the last two-year period over the remaining 125 items totaling \$2,294,506 as required.

Cause

The cause of this finding is due to a lapse in control operation to ensure that the required physical inventory of equipment (or other capitalized assets) acquired under Federal awards was performed by the University at least once every two years.

Effect

The required physical inventory of equipment (or other capitalized assets) acquired under Federal awards was not performed by the University for 5 departments at least once every two years for R&D related equipment.

Questioned Costs

None.

Recommendation

Management should enhance the control in place to ensure that all departments with equipment acquired under Federal Awards are performing the physical inventory when it is requested and ensure that all equipment is verified at least once every two years.

Management's View and Corrective Action Plan

Management's response is included in "Management's Views and Corrective Action Plan" included in this report.

Thomas Jefferson University

Federal Awards

Schedule of Findings and Questioned Costs

June 30, 2023

Finding 2023-003 Retention Payments

Grantor(s): American Rescue Plan Act (ARPA)

Program: American Rescue Plan Act 2 of 2022

Assistance Listing#: 21.027

Title: Coronavirus State and Local Fiscal Recovery Funds

Award Year: 7/2022 – 6/2023

Award #: N/A

Pass-through Number: 4100086662

Criteria

The funds received under Act 2 of 2022 are American Rescue Plan Act funds and are specifically for staff recruitment and retention payments. Recipients do not need to wait until they receive the payments to make payments to qualified staff, but they must spend the funds within the required timeframes. Act 2 of 2022 requires recipients to spend retention payments within 90 calendar days and recruitment payments within 180 calendar days of receipt of the funds. Additionally, hospitals and behavioral health providers may not use the money to pay more than one retention or recruitment payment to qualified staff with Act 2 of 2022 funding.

Condition

The University received the payments from Act 2 of 2022 on April 20, 2022, and therefore had 90 days to spend the retention payments. Of the \$15,674,844 of retention payments spent by the University, 26 payments totaling \$25,836 were spent after the performance period ended (7/19/2022). Additionally, the University reported more than one retention payment to 34 qualified staff members amounting to \$31,530.

Cause

The cause of this finding is due to insufficient review of the details of retention payments paid with funds received from this program, specifically as it relates to the required 90-day window to make retention payments and the restriction on the quantity of payments to an individual with funds from this program.

Effect

Retention payments were spent after the performance period's end, and employees received more than one payment, which resulted in the dollar value of federal expenditures reported in the SEFA being overstated by \$57,365.

Questioned Costs

None.

Recommendation

If the University receives further funding from this program, management should ensure that any future payments from this program are made within the specified timeline and with the appropriate frequency per the program's requirements. Additionally, management should contact the Pennsylvania Department of Human Services to determine if any required corrective action related to the error of \$58,442.

Management's View and Corrective Action Plan

Management's response is included in "Management's Views and Corrective Action Plan" included in this report.

Thomas Jefferson University
Federal Awards
Schedule of Findings and Questioned Costs
June 30, 2023

Finding 2023-004 Enrollment Reporting

Grantor(s): Department of Education
Program: Student Financial Aid Cluster
Assistance Listing#(s): Various
Title: Student Financial Aid Cluster
Award Year: 7/2021 – 6/2022
Award #: N/A
Pass-through Number: N/A

Criteria

Per the OMB Compliance Supplement, institutions are required to certify enrollment, including changes in students' enrollment status, at a minimum of every 65 days. Institutions are responsible for timely reporting, whether they report directly or via a third-party servicer.

Condition

Through testing a sample of 25 students for enrollment reporting of Pell and Direct Loans, we noted 3 students were reported to the NSLDS outside of the required 65-day window. Each of these 3 students were reported 66 days after their status change.

Additionally, for 3 other students in our sample of 25, there was no evidence to support their "graduated" status or date of the status change within the NSLDS.

Cause

The cause of the delay in reporting to the NSLDS for the first 3 students mentioned above is due to timing with graduation and resource constraints at the University during fiscal year 2022.

For the second 3 students, the cause was due to the fact that these students had multiple status changes in a small period of time. The students were "full-time" until 12/31/2021 when they graduated the undergraduate program, then began the graduate program as full-time students in February 2022. The quick change in status was the cause of the NSLDS enrollment status not being supported for these students during fiscal year 2022.

Effect

NSLDS was not updated timely for the first 3 students mentioned above. For the second 3 students, their enrollment status could potentially be inaccurate in the NSLDS system if their graduation was not processed.

Questioned Costs

None.

Recommendation

Management should enhance their resources within the office of the registrar to be able to accommodate status changes during the graduation period and ensure timely status change submission to the NSLDS.

Management's View and Corrective Action Plan

Management's response is included in "Management's Views and Corrective Action Plan" included in this report.

Thomas Jefferson University
Federal Awards
Summary Schedule of Prior Audit Findings
June 30, 2023

Section III – Status of Prior Year Findings

Finding 2022-001 Reporting

Grantor(s): Department of Education
Assistance Listing#: 84.038; Student Financial Aid Cluster
Title: Federal Perkins Loans; Student Financial Aid Cluster
Award Year: 7/2021 – 6/2022

Criteria

Per the 2022 OMB Compliance Supplement, an institution is required to maintain program and fiscal records for all transactions that occurred after the most recent Fiscal Operations Report and Application to Participate (FISAP) was filed. As part of its procedures, the program should ensure that overall cash-on-hand or excess cash amounts are reconciled.

Condition

Through testing the Student Financial Assistance cluster in the 2022 Uniform Guidance audit, we noted that there were two line-items on the FISAP that did not agree to supporting documentation with reportable differences larger than \$25,000. Within the Federal Perkins Loan section, field item 1.1 “Cash on hand and in depository as of 6/30/2022” was understated by \$378,201, while field item 1.2 “Cash on hand and in depository as of 10/31/2022” was overstated by \$113,754.

Status

The original remediation plan was successfully implemented. Management implemented an enhanced review process prior to the FISAP submission for FY23, which included measures to agree reported amounts to Federal Perkins Loan information maintained by a third-party service provider. Additionally, the FISAP for June 30, 2022, was resubmitted to the Department of Education to restate reported amount of “Cash on hand and in depository as of 6/30/2022” in accordance with the audit findings.

Management considers this finding to be closed.

Thomas Jefferson University
Federal Awards
Summary Schedule of Prior Audit Findings
June 30, 2023

Finding 2022-002 Special Tests and Provisions – Disbursements to or on behalf of students

Grantor(s): Department of Education
Assistance Listing#(s): Student Financial Aid Cluster
Title: Student Financial Aid Cluster
Award Year: 7/2021 – 6/2022

Criteria

Per the 2022 OMB Compliance Supplement, where disbursements created a credit balance in the student account and the student or parent did not provide an authorization for the institution to retain funds, the institution is required to provide the credit balance to the student within 14 days of the date the balance was created.

Condition

Through testing disbursements to or on behalf of students enrolled at the East Falls campus, it was noted that 1 student of a sample of 25 had a credit balance that was not refunded within the required 14-day period. For this particular student, the credit balance was created on 10/18/2021 and refunded to the student on 11/15/2021, which is 28 days later.

Status

The original remediation plan was successfully implemented. On a daily basis, student accounts are analyzed to identify credit balances and refund amounts payable to students. If necessary, refund disbursements are initiated.

Management considers this finding to be closed.

Thomas Jefferson University
Federal Awards
Summary Schedule of Prior Audit Findings
June 30, 2023

Finding 2022-003 Enrollment Reporting

Grantor(s): Department of Education
Assistance Listing#(s): Student Financial Aid Cluster
Title: Student Financial Aid Cluster
Award Year: 7/2021 – 6/2022

Criteria

Per the 2022 OMB Compliance Supplement, institutions are required to certify enrollment, including changes in students' enrollment status, at a minimum of every 60 days. Institutions are responsible for timely reporting, whether they report directly or via a third-party servicer.

Condition

Through testing a sample of 25 students for enrollment reporting of Pell and Direct Loans, we noted 3 students were reported to the NSLDS outside of the required 65-day window. Each of these 3 students were reported 66 days after their status change.

Additionally, for 3 other students in our sample of 25, there was no evidence to support their "graduated" status or date of the status change within the NSLDS.

Status

As noted in finding 2023-004 of the Summary of Current Year Findings, the original remediation plan was partially implemented but is still open. We will continue to follow the corrective action plan outlined in the prior fiscal year. We have seen significant increases in accuracy for the summer term by making enrollment priorities for the June submission and employing most of the measures in the corrective action plan. Additionally, the University Registrar obtained direct access to NSLDS to update any record that was erroneously reported or to correct inconsistencies that are found between NSC and NSLDS. However, the University Registrar continues to work with the NSLDS and National Student Clearing House to locate the cause of the errors in the NSLDS roster records.

Management considers this finding to be partially closed, refer to the "Management's Views and Corrective Action Plan" included in this report for further information.



2023-001: Reporting of PRF Expenses

Management's view and corrective action plan

Management concurs that the Period 4 PRF Reporting Portal Submission for Jefferson University Physicians included a duplicate reporting of expenses of \$133,333 from Period 3 resulting in the reported amount of \$24,889,847 for "Total Unused Lost Revenues Available for Future Reporting Periods" being overstated by the \$133,333 and the reported amount of \$3,084,081 for "Total Payments Used for Lost Revenues in the Current Reporting Period" being understated by \$133,333. Management identified the duplicate reporting in September 2023 and contacted HRSA in an attempt to amend the Period 4 submission. A HRSA representative advised the PRF Reporting Portal Submission for Period 4 could not be amended. Management will implement an enhanced review process to validate all amounts reported on the PRF Reporting Portal Submission.

Implementation date: April 2024

2023-002: Equipment Observations R&D

Management's view and corrective action plan

Management concurs that the required physical inventory of equipment acquired under Federal award was not performed for 5 departments at least once every two years for R&D related equipment. Management will implement enhanced control procedures to ascertain the physical inventory of equipment is performed bi-annually.

Implementation date: April 2024

2023-003: Retention Payments

Management's view and corrective action plan

For expenditures made pursuant to the American Rescue Plan Act funds received pursuant to Act 2 of 2022, management concurs there were 26 payments totaling \$25,836 made after the 90-day performance period ended and more than one retention payment was made to 34 qualified staff members amounting to \$31,530. Management will contact the Pennsylvania Department of Human Services and inform them of this finding to determine the appropriate corrective measures.

Implementation date: April 2024

Ronald Keller
Vice President for Finance & Controller

2023-004: Enrollment Reporting

Management's view and corrective action plan

Management concurs with the findings regarding the delay and insufficient graduation reporting to NSLDS. The University Registrar is aware of the 6-day delinquency in reporting for summer term due to the timing of the degree awards for the May graduates on the East Falls campus. Degree audits will be checked to ensure are awarded in a timely manner. We also will work with NSC to ensure all enrollment reporting schedules are updated in accordance with the academic calendar of the appropriate branch, limiting any issue with the 60-day certification date during our Summer term, as all other terms have been reported correctly. This will happen every semester on a 4–6 week basis, in tandem with enrollment report submissions. This will resolve the 60-day certification issue.

Academic Services makes every effort to report clean enrollments accurately and on time. However, we continue to find inconsistencies with the NSC transmissions to NSLDS and are aware of the need for additional oversight of the NSC process as well as the development of a process to audit NSC transmissions to NSLDS. This will also aid in the elimination of reporting errors between NSC and NSLDS, as in the case of the three graduation records. The Office of Academic Services is working to identify resources to address the above action plans.

Spring 2024 update:

The University Registrar has gained access directly to the NSLDS enrollment files. The University Registrar will audit enrollment files twice monthly to be certain that any errored NSLDS enrollment records created at the time of NSLDS roster submission, are corrected to negate the 65-day outstanding record (NSLDS ERROR 22). The University Registrars will continue to work with NSLDS and National Student Clearinghouse to locate cause of errored NSLDS roster records.

Implementation date: July 2024



Kris Peluszak
University Registrar

IV. Supplementary Information

Schedule of Expenditures of Federal Awards Supplementary Schedules

Thomas Jefferson University
Federal Awards
Schedule of Expenditures of Federal Awards Supplementary Schedules (Unaudited)
Year Ended June 30, 2023

Schedule of Expenditures of Commonwealth of Pennsylvania Awards

<u>Award</u>	Assistance Listing #	Federal Funding Received in FY	Accrued Federal Revenue at Beginning of FY	Federal Revenue Recognized in FY	Accrued Federal Revenue at End of FY
Department of Health					
SAP# 4100079801		79,707	147,109	77,477	224,586
SAP# 4100090947		-	4,455	201,606	206,061
		<u>79,707</u>	<u>151,564</u>	<u>279,084</u>	<u>430,647</u>
Department of Human Services					
SM58386	93.243	-	106,132	1,408	107,540
H79SM082107	93.243	338,307	855,462	176,453	1,031,915
H79SM083371	93.243	262,853	222,895	144,022	366,917
4000025628	93.243	-	66,188	12,873	79,061
H79SM086062	93.243	804,179	-	169,736	169,736
		<u>1,405,339</u>	<u>1,250,677</u>	<u>504,493</u>	<u>1,755,169</u>
		<u>1,485,046</u>	<u>1,402,241</u>	<u>783,576</u>	<u>2,185,817</u>

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Federal Awards
Schedule of Expenditures of Federal Awards Supplementary Schedules (Unaudited)
Year Ended June 30, 2023

Schedule of Expenditures of State of New Jersey Awards

State of Grantor/Program	Contract Number	Grant Period	Total Expenditures
HIV/AIDS Care and Treatment 2023			
HIV/AIDS Care and Treatment -Mental Health	DHST22HIV045	01/01/22-06/30/22	29,022
HIV/AIDS Care and Treatment -Mental Health	DHST23HIV041	07/01/22-06/30/23	671,954
			<u>700,976</u>
Total State of New Jersey Department of Health and Senior Services			<u>700,976</u>

The accompanying notes are an integral part of this schedule

Thomas Jefferson University
Federal Awards
Schedule of Expenditures of Federal Awards Supplementary Schedules
(Unaudited)
Year Ended June 30, 2023

1 General Information

The accompanying schedules of Program Expenditures and Revenue present the activities in all the state financial assistance programs of the Commonwealth of Pennsylvania and the State of New Jersey at the University. All financial assistance received directly from the state agencies are included on the schedule.

2 Basis of Presentation

The accompanying Schedules of Program Expenditures and Program Revenue have been prepared in the format set forth in the Commonwealth of Pennsylvania and the State of New Jersey Audit Guides. Revenues and expenditures are recognized using the accrual method of accounting.

Thomas Jefferson University

Federal Awards

Schedule of Financial Responsibility Ratios

Year Ended June 30, 2023

Line	Reference	Financial Element Primary Reserve Ratio	Amount
<u>Expendable Net Assets:</u>			
44	Consolidated Balance Sheets - Net assets without donor restrictions	Net assets without donor restrictions	\$ 3,976,074
45	Consolidated Balance Sheets - Net assets with donor restrictions	Net assets with donor restrictions	1,156,515
	N/A	Secured and unsecured related party receivable	-
	N/A	Less: Unsecured related party receivables	-
18	Consolidated Balance Sheets - Land, buildings and equipment, net	Property, plant, and equipment, net (includes construction in progress)	4,188,135
	N/A	Less: Property, plant, and equipment- pre-implementation	-
	N/A	Less: Property, plant, and equipment- post-implementation with outstanding debt for original purchase	-
	Consolidated Balance Sheets - Land, buildings and equipment, net (excluding Construction in Process)	Less: Property, plant, and equipment- post-implementation without outstanding debt for original purchase	3,412,856
	Note 11 - Land, Buildings And Equipment in the Notes to the Consolidated Financial Statements	Less: Construction in Process	775,279
19	Consolidated Balance Sheets - Right-of-use assets	Lease right-of-use asset, net	310,609
	N/A	Less: Lease right-of-use asset, pre-implementation	-
19	Consolidated Balance Sheets - Right-of-use assets	Less: Lease right-of-use asset, post-implementation	310,609
15	Consolidated Balance Sheets - Goodwill	Less: Intangible assets	246,109
34	Consolidated Balance Sheets - Accrued pension liability	Post-employment and retirement liabilities	243,893
22, 33	Consolidated Balance Sheets - Long-term obligations	Long-term debt- for long term purposes	3,515,717
	N/A	Long-term debt- for long term purposes pre-implementation	-
22, 33	Consolidated Balance Sheets - Long-term obligations	Long-term debt- for long term purposes post-implementation	3,515,717
	N/A	Line of credit for construction in progress	-
27, 39	Consolidated Balance Sheets - Current portion of operating lease obligations and Long-term operating lease obligations	Lease right-of-use asset liability, net	361,509
	N/A	Pre-implementation right-of-use asset liability	-
27, 39	Consolidated Balance Sheets - Current portion of operating lease obligations and Long-term operating lease obligations	Post-implementation right-of-use asset liability	361,509
	Note 6 - Investments in the Notes to the Consolidated Financial Statements	Less: Annuities with donor restrictions	14,115
	N/A	Less: Term endowments with donor restrictions	-
	N/A	Less: Life income funds with donor restrictions	-
	Note 7 - Endowment Funds in the Notes to the Consolidated Financial Statements	Less: Net assets with donor restrictions: restricted in perpetuity	724,458
		Total Expendable Net Assets:	\$ 3,770,282
<u>Expenses and Losses Without Donor Restriction:</u>			
68	Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions - Total expenses	Total expenses without donor restrictions	\$ 9,779,034
73,75,78	Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions - (Loss)Gain on investment in acquisition, , Reclassification of net assets, Distributions to noncontrolling interest,	Non-operating and net investment loss	(8,299)
	N/A	Less: Net investment loss	-
	N/A	Less: Change in the value of life income funds	-
	N/A	Less: Pension related changes other than net periodic costs	-
		Total Expenses and Losses Without Donor Restriction:	\$ 9,770,735
<u>Modified Net Assets:</u>			
44	Consolidated Balance Sheets - Net assets without donor restrictions	Equity Ratio	
45	Consolidated Balance Sheets - Net assets with donor restrictions	Net assets without donor restrictions	\$ 3,976,074
15	Consolidated Balance Sheets - Goodwill	Net assets with donor restrictions	1,156,515
	N/A	Less: Intangible assets	246,109
		Less: Unsecured related party receivables	-
		Total Modified Net Assets:	\$ 4,886,480
<u>Modified Assets:</u>			
21	Consolidated Balance Sheets - Total Assets	Total assets	\$ 11,771,868
	N/A	Less: Lease right-of-use asset, pre-implementation	-
	N/A	Less: Lease right-of-use liability, pre-implementation	-
15	Consolidated Balance Sheets - Goodwill	Less: Intangible assets	246,109
	N/A	Less: Unsecured related party receivables	-
		Total Modified Assets:	\$ 11,525,759
<u>Change in Net Assets Without Donor Restrictions:</u>			
81	Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions - Increase in net assets without donor restriction	Change in net assets without donor restrictions	\$ 209,634
		Total Change in Net Assets Without Donor Restrictions:	\$ 209,634
<u>Revenues and Gains Without Donor Restriction:</u>			
57, 71, 72, 74, 76, 77,79	Consolidated Statements of Operations and Changes in Net Assets without Donor Restrictions - Total revenue, gains, and other support, Return on investments, net of amounts classified as operating revenue, Value of noncontrolling interest, Interest rate hedges, Net assets released from restrictions used for purchase of property and equipment, Decrease in pensin liability, Other	Total operating revenue and other additions (gains)	\$ 9,996,967
		Total Revenues and Gains Without Donor Restrictions:	\$ 9,996,967

Thomas Jefferson University

Federal Awards

Schedule of Financial Responsibility Ratios

Year Ended June 30, 2023

Consolidated Balance Sheet

Line		
	Assets	
	Current assets:	
1	Cash and cash equivalents	\$743,046
2	Short-term investments	860,162
3	Accounts receivable	873,006
4	Insurance premium receivable	214,653
5	Inventory	151,767
6	Pledges receivable, current	41,266
7	Insurance recoverable, current	147,351
8	Assets whose use is limited, current	1,915
9	Other current assets	141,573
10	Total current assets	3,174,739
11	Long-term investments	2,954,704
12	Assets whose use is limited, noncurrent	209,986
13	Assets held by affiliated foundations	44,781
14	Pledges receivable, noncurrent	111,262
15	Goodwill	246,109
16	Insurance recoverable, noncurrent	316,575
17	Loans receivable from students, net	19,562
18	Land, buildings and equipment, net	4,188,135
19	Right-of-use assets	310,609
20	Other noncurrent assets	195,406
21	Total assets	\$11,771,868
	Liabilities and Net Assets	
	Current liabilities:	
	Current portion of:	
22	Long-term obligations	\$47,818
23	Accrued professional liability claims	233,308
24	Accrued workers' compensation claims	17,633
25	Deferred revenues	29,739
26	Advances	19,536
27	Operating lease obligations	48,911
28	Accounts payable and accrued expenses	621,024
29	Medical costs payable	183,363
31	Accrued payroll and related costs	462,218
32	Total current liabilities	1,808,132
33	Long-term obligations	3,467,899
34	Accrued pension liability	243,893
35	Federal student loan advances	5,254
36	Accrued professional liability claims	663,336
37	Accrued workers' compensation claims	26,396
38	Interest rate hedges	11,987
39	Operating lease obligations	312,598
40	Other noncurrent liabilities	99,784
41	Total liabilities	6,639,279
	Net assets:	
42	Net assets without donor restriction - Thomas Jefferson University	3,933,422
43	Noncontrolling interest in joint ventures	42,652
44	Total net assets without donor restriction	3,976,074
45	Net assets with donor restriction	1,156,515
46	Total net assets	5,132,589
47	Total liabilities and net assets	\$11,771,868

Consolidated Statement of Operations and Changes in Net Assets Without Donor Restriction

	Operating revenues, gains and other support:		
48	Net patient service revenue	\$6,119,905	
49	Insurance premium revenue	2,148,677	
50	Grants and contracts	168,360	
51	Tuition and fees, net	223,153	
52	Investment income	163,899	
53	Contributions	5,387	
54	Other revenue	750,993	
55	Government support for COVID-19	48,584	
56	Net assets released from restrictions	71,529	
57	Total operating revenues, gains and other support	9,700,487	
	Operating expenses:		
58	Salaries and wages	3,751,152	
59	Employee benefits	884,329	
60	Insurance services medical expenses	1,593,742	
61	Supplies	1,357,436	
62	Purchased services	855,947	
63	Depreciation and amortization	358,567	
64	Interest	116,406	
65	Insurance	160,249	
66	Utilities	70,509	
67	Other	630,497	
68	Total operating expenses	9,779,034	
69	Loss from operations	(78,547)	
	Nonoperating items and other changes in net assets without donor restriction, net:		
70	Return on investments, net of amounts classified as operating revenue	106,827	Gain
71	Value of noncontrolling interest	28,386	Gain
72	(Loss) Gain on investment in acquisitions	(1,410)	Loss
73	Interest rate hedges	4,923	Gain
74	Reclassification of net assets	(889)	Loss
75	Net assets released from restrictions used for purchase of property and equipment	4,401	Gain
76	Decrease in pension liability	151,582	Gain
77	Other	361	Gain
78	Increase in nonoperating items and other changes in net assets without donor restriction	288,181	
81	Increase in net assets without donor restriction	\$209,634	

Thomas Jefferson University
Federal Awards
Schedule of Financial Responsibility Ratios
Year Ended June 30, 2023

Basis of Presentation

The accompanying Schedule of Financial Responsibility Ratios (the “Supplemental Schedule”) of Thomas Jefferson University (the “University”) provides financial information required by the Department of Education to calculate the primary reserve ratio, equity ratio, net income ratio and the composite score as defined in Title 34 U.S. Code of Federal Regulations Part 668 Subpart L for the fiscal year-ended June 30, 2023. The financial information in the Supplemental Schedule has been prepared in accordance with accounting principles generally accepted in the United States of America consistent with the financial statements. The Supplemental Schedule is presented for purposes of additional analysis as required by the Department of Education and are not a required part of the financial statements.